{"bill": {"#text": "\n  ", "form": {"current-chamber": {"#tail": "\n    ", "#text": "IN THE HOUSE OF REPRESENTATIVES"}, "#text": "\n", "congress": {"#tail": "\n    ", "#text": "113th CONGRESS"}, "#tail": "\n  ", "legis-num": {"#tail": "\n    ", "#text": "H. R. 3116"}, "official-title": {"#tail": "\n  ", "#text": "To promote the development of meaningful treatments for patients."}, "session": {"#tail": "\n    ", "#text": "1st Session"}, "distribution-code": {"#tail": "\n    ", "@display": "yes", "#text": "I"}, "action": {"action-date": {"#tail": "\n      ", "@date": "20130917", "#text": "September 17, 2013"}, "#tail": "\n    ", "action-desc": {"#tail": "\n    ", "#text": "\n        ", "committee-name": [{"#tail": ", and in addition to the Committees on ", "@committee-id": "HIF00", "#text": "Committee on Energy and Commerce"}, {"#tail": " and ", "@committee-id": "HWM00", "#text": "Ways and Means"}, {"#tail": ", for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned", "@committee-id": "HJU00", "#text": "the Judiciary"}], "sponsor": {"#tail": " (for himself, ", "#text": "Mr. Lance", "@name-id": "L000567"}, "cosponsor": [{"#tail": ", ", "#text": "Mr. Roskam", "@name-id": "R000580"}, {"#tail": ", ", "#text": "Mr. Guthrie", "@name-id": "G000558"}, {"#tail": ", ", "#text": "Mr. Paulsen", "@name-id": "P000594"}, {"#tail": ", ", "#text": "Mr. Rangel", "@name-id": "R000053"}, {"#tail": ", ", "#text": "Mr. Runyan", "@name-id": "R000594"}, {"#tail": ", ", "#text": "Ms. Schwartz", "@name-id": "S001162"}, {"#tail": ", ", "#text": "Mr. King of New York", "@name-id": "K000210"}, {"#tail": ", ", "#text": "Mr. McCaul", "@name-id": "M001157"}, {"#tail": ", ", "#text": "Mr. Walden", "@name-id": "W000791"}, {"#tail": ", ", "#text": "Mr. Tiberi", "@name-id": "T000462"}, {"#tail": ", ", "#text": "Mr. Loebsack", "@name-id": "L000565"}, {"#tail": ", ", "#text": "Mr. Ben Ray Luj\u00e1n of New Mexico", "@name-id": "L000570"}, {"#tail": ", ", "#text": "Mr. Ellison", "@name-id": "E000288"}, {"#tail": ", and ", "#text": "Mr. Jones", "@name-id": "J000255"}, {"#tail": ") introduced the following bill; which was referred to the ", "#text": "Mr. Long", "@name-id": "L000576"}]}, "#text": "\n      "}, "legis-type": {"#tail": "\n    ", "#text": "A BILL"}}, "@bill-stage": "Introduced-in-House", "@bill-type": "olc", "@dms-id": "H7D54B00A31AE495E93648E5A58DAD584", "@public-private": "public", "legis-body": {"@style": "OLC", "title": [{"#tail": "\n    ", "section": [{"#tail": "\n      ", "enum": {"#tail": "\n        ", "#text": "101."}, "header": {"#tail": "\n        ", "#text": "Developing a common lexicon to facilitate progress on diagnostics"}, "subsection": [{"#tail": "\n        ", "text": {"#tail": "\n        ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall establish within the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " the ", "@entity-type": "federal-body", "#text": "Department of Health and Human Services", "@entity-id": "7500"}, {"@proposed": "true", "#tail": " (in this section referred to as the ", "@entity-type": "federal-body", "@value": "Advanced Diagnostics Education Council", "@entity-parent-id": "7500", "#text": "Advanced Diagnostics Education Council"}], "quote": {"short-title": {"#tail": "\n            ", "#text": "Council"}, "#tail": ").", "#text": "\n              "}, "#text": "Not later than 180 days after the date of enactment of this Act, the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(a)"}, "header": {"#tail": "\n          ", "#text": "In general"}, "#text": "\n          ", "@id": "HF664ADF5DF814067B68A31946BB5FB04"}, {"#tail": "\n        ", "enum": {"#tail": "\n          ", "#text": "(b)"}, "header": {"#tail": "\n          ", "#text": "Duties"}, "paragraph": [{"#tail": "\n          ", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": {"@proposed": "true", "#tail": " shall promote an improved understanding of key concepts related to innovative diagnostics by recommending standard terms and definitions for use by patients, physicians, health care providers, payers, and policymakers.", "@entity-type": "federal-body", "@value": "Advanced Diagnostics Education Council", "@entity-parent-id": "7500", "#text": "Council"}, "#text": "The "}, "enum": {"#tail": "\n            ", "#text": "(1)"}, "header": {"#tail": "\n            ", "#text": "In general"}, "#text": "\n            ", "@id": "H8F74ED9625154BD8964287867C319F86"}, {"#tail": "\n          ", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall publish and disseminate a guide regarding such recommended terms and definitions for patients, physicians, health care providers, payers, and policymakers.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "The ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n            ", "#text": "(2)"}, "header": {"#tail": "\n            ", "#text": "Guide"}, "#text": "\n            ", "@id": "H37FAE13AC259411AB6A22AAF125C292B"}, {"#tail": "\n        ", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"@proposed": "true", "#tail": ", the ", "@entity-type": "federal-body", "@value": "Advanced Diagnostics Education Council", "@entity-parent-id": "7500", "#text": "Council"}, {"#tail": " shall prepare and submit a report to the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " and to the public on the ", "@entity-type": "federal-body", "#text": "Congress", "@entity-id": "0001"}, {"@proposed": "true", "#tail": " deliberations, activities, and determinations with respect to meeting its duties described in ", "@entity-type": "federal-body", "@value": "Advanced Diagnostics Education Council", "@entity-parent-id": "7500", "#text": "Council\u2019s"}, {"#tail": " and ", "@entity-type": "act", "#text": "paragraphs (1)", "@value": "MODDERN Cures Act of 2013/s:101/ss:b/p:1", "@proposed": "true"}, {"#tail": ".", "@entity-type": "act", "#text": "(2)", "@value": "MODDERN Cures Act of 2013/s:101/ss:b/p:2", "@proposed": "true"}], "#text": "Not later than 12 months after the establishment of the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n            ", "#text": "(3)"}, "header": {"#tail": "\n            ", "#text": "Report"}, "#text": "\n            ", "@id": "HE6D001AC8233438FB2FDC43CFFD18684"}], "#text": "\n          ", "@id": "HB6FD294B435F4E579B0CB9853128E53D"}, {"#tail": "\n        ", "text": {"#tail": "\n        ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", or the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " designee, shall serve as chairperson of the ", "@entity-type": "federal-body", "#text": "Secretary\u2019s", "@entity-id": "7500"}, {"@proposed": "true", "#tail": ".", "@entity-type": "federal-body", "@value": "Advanced Diagnostics Education Council", "@entity-parent-id": "7500", "#text": "Council"}], "#text": "The ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(c)"}, "header": {"#tail": "\n          ", "#text": "Chairperson"}, "#text": "\n          ", "@id": "H3C220CA43AAA43A2AE6E910637715182"}, {"#tail": "\n        ", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"@proposed": "true", "#tail": " shall consist of the following:", "@entity-type": "federal-body", "@value": "Advanced Diagnostics Education Council", "@entity-parent-id": "7500", "#text": "Council"}], "#text": "In addition to the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(d)"}, "header": {"#tail": "\n          ", "#text": "Members"}, "paragraph": [{"#tail": "\n          ", "text": {"#tail": "\n            ", "#text": "The head of each of the following agencies (or a designee thereof):", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n            ", "#text": "(1)"}, "#text": "\n            ", "@id": "H647A63A7B20342A1AD79FF8ACA6BA42C", "subparagraph": [{"#tail": "\n            ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "federal-body", "#text": "National Institutes of Health", "@entity-id": "7529"}, "#text": "The ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(A)"}, "@id": "H7CEF888EDF0A441398E91BEBB9600550", "#text": "\n              "}, {"#tail": "\n            ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "federal-body", "#text": "Centers for Disease Control and Prevention", "@entity-id": "7523"}, "#text": "The "}, "enum": {"#tail": "\n              ", "#text": "(B)"}, "@id": "H984064B2C9214466B38C31954F8EB8C1", "#text": "\n              "}, {"#tail": "\n            ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}, "#text": "The "}, "enum": {"#tail": "\n              ", "#text": "(C)"}, "@id": "HC0ECFD5A7CEE41BDB0E0A8CCCD61126C", "#text": "\n              "}, {"#tail": "\n            ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "federal-body", "#text": "Agency for Healthcare Research and Quality", "@entity-id": "7528"}, "#text": "The "}, "enum": {"#tail": "\n              ", "#text": "(D)"}, "@id": "H999DDCCD6D504322B6E4C161E8FE8885", "#text": "\n              "}, {"#tail": "\n            ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "federal-body", "#text": "Centers for Medicare & Medicaid Services", "@entity-id": "7530"}, "#text": "The "}, "enum": {"#tail": "\n              ", "#text": "(E)"}, "@id": "H794CDF8A39804403941AB830375CBCFC", "#text": "\n              "}, {"#tail": "\n            ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "federal-body", "#text": "Department of Defense", "@entity-id": "9700"}, "#text": "The "}, "enum": {"#tail": "\n              ", "#text": "(F)"}, "@id": "H9FFF3A8AF0BA405589C8FF97F2D19129", "#text": "\n              "}, {"#tail": "\n            ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "federal-body", "#text": "Department of Veterans Affairs", "@entity-id": "3600"}, "#text": "The "}, "enum": {"#tail": "\n              ", "#text": "(G)"}, "@id": "HE9E10C7988EC408A8E90A0B0CDED0C8F", "#text": "\n              "}, {"#tail": "\n            ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "federal-body", "#text": "Health Resources and Services Administration", "@entity-id": "7526"}, "#text": "The "}, "enum": {"#tail": "\n              ", "#text": "(H)"}, "@id": "H6B982CFAB87D43D898EC6504EEC42877", "#text": "\n              "}, {"#tail": "\n            ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "federal-body", "#text": "Substance Abuse and Mental Health Services Administration", "@entity-id": "7522"}, "#text": "The "}, "enum": {"#tail": "\n              ", "#text": "(I)"}, "@id": "H45730859218C4448A10627830240CBCD", "#text": "\n              "}, {"#tail": "\n          ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "federal-body", "#text": "Indian Health Service", "@entity-id": "7527"}, "#text": "The "}, "enum": {"#tail": "\n              ", "#text": "(J)"}, "@id": "H4EE0483F4C7840A5B04358575EAAE265", "#text": "\n              "}]}, {"#tail": "\n          ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " from among individuals who collectively\u2014", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "Seven members appointed by the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n            ", "#text": "(2)"}, "#text": "\n            ", "@id": "H1EA41541872B41438D84892B94A03FA7", "subparagraph": [{"#tail": "\n            ", "text": {"#tail": "\n            ", "#text": "represent a broad range of perspectives; and"}, "enum": {"#tail": "\n              ", "#text": "(A)"}, "@id": "H9015A93D973B44D1A40550EF8331A2AD", "#text": "\n              "}, {"#tail": "\n          ", "text": {"#tail": "\n              ", "#text": "have expertise in\u2014"}, "enum": {"#tail": "\n              ", "#text": "(B)"}, "clause": [{"#tail": "\n              ", "text": {"#tail": "\n              ", "#text": "basic and translational research, including with respect to molecular biology and genetics;", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(i)"}, "@id": "H5091D349A263492F9FD5764CD1EA56E0", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n              ", "#text": "bioinformatics;"}, "enum": {"#tail": "\n                ", "#text": "(ii)"}, "@id": "HD2F3124D8D0B4D41900C835DFEDA3A7B", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n              ", "#text": "the discovery, development, and commercialization of in vitro diagnostics; and"}, "enum": {"#tail": "\n                ", "#text": "(iii)"}, "@id": "HBBF9FB13575045828AC12AFB3A82C31A", "#text": "\n                "}, {"#tail": "\n            ", "text": {"#tail": "\n              ", "#text": "law and ethics."}, "enum": {"#tail": "\n                ", "#text": "(iv)"}, "@id": "H9EB70CE93AB44B89B675CE5357626C16", "#text": "\n                "}], "#text": "\n              ", "@id": "H67478F5CDBE94CB0822A883CDD6C2244"}]}, {"#tail": "\n        ", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " who are each a chief medical or scientific officer of a patient advocacy organization.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "Four members appointed by the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n            ", "#text": "(3)"}, "@id": "HEFAEEC24D6B741D8B2CD0736C22DDCEA", "#text": "\n            "}], "#text": "\n          ", "@id": "HC2FFAF0D8E8C42AC9ACD81C3FE6992D0"}, {"#tail": "\n        ", "text": {"#tail": "\n        ", "{http://namespaces.cato.org/catoxml}entity-ref": {"@proposed": "true", "#tail": " shall solicit input from relevant stakeholders and the public.", "@entity-type": "federal-body", "@value": "Advanced Diagnostics Education Council", "@entity-parent-id": "7500", "#text": "Council"}, "#text": "In carrying out its duties, the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(e)"}, "header": {"#tail": "\n          ", "#text": "Public input"}, "#text": "\n          ", "@id": "H8D4B65C34D1E428C841523A3203C6920"}, {"#tail": "\n      ", "text": {"#tail": "\n        ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"@proposed": "true", "#tail": " shall terminate after publishing the guide required by ", "@entity-type": "federal-body", "@value": "Advanced Diagnostics Education Council", "@entity-parent-id": "7500", "#text": "Council"}, {"#tail": " and submitting the report required by ", "@entity-type": "act", "#text": "subsection (b)(2)", "@value": "MODDERN Cures Act of 2013/s:101/ss:b/p:2", "@proposed": "true"}, {"#tail": ", or later at the discretion of the ", "@entity-type": "act", "#text": "subsection (b)(3)", "@value": "MODDERN Cures Act of 2013/s:101/ss:b/p:3", "@proposed": "true"}, {"#tail": ".", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "The ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(f)"}, "header": {"#tail": "\n          ", "#text": "Termination"}, "#text": "\n          ", "@id": "H5607EC6B005845B589278900595A495A"}], "#text": "\n        ", "@id": "HC72E66CD7B7D4F23A4532F9925B22DD0"}, {"#tail": "\n      ", "enum": {"#tail": "\n        ", "#text": "102."}, "header": {"#tail": "\n        ", "#text": "Creating incentives for innovative diagnostics"}, "subsection": [{"#tail": "\n        ", "enum": {"#tail": "\n          ", "#text": "(a)"}, "header": {"#tail": "\n          ", "#text": "Improvements To process for determining fee schedule amounts for new tests"}, "paragraph": [{"#tail": "\n          ", "@id": "H707FCA952D274445AF8005EF71594B7D", "enum": {"#tail": "\n            ", "#text": "(1)"}, "header": {"#tail": "\n            ", "#text": "Clarifying factors for rate-setting"}, "text": {"{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (in this section referred to as the ", "@entity-type": "federal-body", "#text": "Secretary of Health and Human Services", "@entity-id": "7500"}, "term": {"#tail": ") shall take into account, as applicable and available, the following factors with respect to such a new test:", "#text": "Secretary"}, "#tail": "\n            ", "external-xref": {"#tail": " of title 42, Code of Federal Regulations, or any successor regulation to such section) for new clinical diagnostic laboratory tests under ", "@parsable-cite": "cfr/42/414.508", "#text": "section 414.508(b)", "@legal-doc": "regulation"}, "{http://namespaces.cato.org/catoxml}entity": {"#tail": ", the ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 1833(h)(8) of the Social Security Act", "@value": "Social Security Act/s:1833/ss:h/p:8"}, "@entity-type": "law-citation", "#text": "\n                ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                ", "@entity-type": "uscode", "#text": "42 U.S.C. 1395l(h)(8)", "@value": "usc/42/1395l/h/8"}, "@parsable-cite": "usc/42/1395l", "#text": "\n                  ", "@legal-doc": "usc"}}, "@display-inline": "yes-display-inline", "#text": "In determining the payment amount under gapfilling procedures (as described in "}, "#text": "\n            ", "subparagraph": [{"#tail": "\n            ", "text": {"#tail": "\n            ", "#text": "The impact of the new test on patient care, patient management, or patient treatment.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(A)"}, "header": {"#tail": "\n              ", "#text": "Impact on patient care"}, "#text": "\n              ", "@id": "H90DEC24C0C8D4F5889238B5504AB066B", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n            ", "#text": "The technical characteristics of the new test, and the resources required to develop, validate, and perform the new test.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(B)"}, "header": {"#tail": "\n              ", "#text": "Technical characteristics"}, "#text": "\n              ", "@id": "H1E311DB4FF024CD09FE3A549E5AE93B2", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "act", "#text": "part B of title XVIII of the Social Security Act", "@value": "Social Security Act/t:XVIII/pt:B"}, "#text": "Data from claims for which payment is made under ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(C)"}, "header": {"#tail": "\n              ", "#text": "Claims data"}, "#text": "\n              ", "@id": "HDCBD9400DD7947E89D6D6D68DF659D73", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n            ", "#text": "Amounts charged by laboratories to self-pay patients for the new test.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(D)"}, "header": {"#tail": "\n              ", "#text": "Laboratory charges"}, "#text": "\n              ", "@id": "HC539C8E743A64D33A5932F3D44C1BA3E", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n            ", "#text": "Amounts paid to laboratories for such new test under private health insurance coverage offered in the group market and the individual market.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(E)"}, "header": {"#tail": "\n              ", "#text": "Private insurance rates"}, "#text": "\n              ", "@id": "HB91FEAF2F5F54235A746EBB1F1238222", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " with respect to that new test and any comments received during the open meeting of the advisory panel.", "@entity-type": "act", "#text": "paragraph (2)", "@value": "MODDERN Cures Act of 2013/s:102/ss:a/p:2", "@proposed": "true"}, "#text": "The findings and recommendations of the independent advisory panel convened under ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(F)"}, "header": {"#tail": "\n              ", "#text": "Advisory panel recommendations"}, "#text": "\n              ", "@id": "HC1A708E618064E89A13CF1DE860D859E", "@commented": "no"}, {"#tail": "\n          ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " may specify.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "Such other factors as the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(G)"}, "header": {"#tail": "\n              ", "#text": "Additional factors"}, "#text": "\n              ", "@id": "H99EF519374E94C00A8690FFE8F613F58", "@commented": "no"}], "@commented": "no"}, {"#tail": "\n          ", "subparagraph": [{"#tail": "\n            ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall convene an independent advisory panel from which the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " shall request information and recommendations regarding any new test (as referred to under ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "The ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": ") for which payment is made under such section, including technical, clinical, and quality information.", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "subparagraph (A) of section 1833(h)(8) of the Social Security Act", "@value": "Social Security Act/s:1833/ss:h/p:8/sp:A"}, "@entity-type": "law-citation", "#text": "\n                  ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                  ", "@entity-type": "uscode", "#text": "42 U.S.C. 1395l(h)(8)", "@value": "usc/42/1395l/h/8"}, "@parsable-cite": "usc/42/1395l", "#text": "\n                    ", "@legal-doc": "usc"}}, "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(A)"}, "header": {"#tail": "\n              ", "#text": "Requirement for independent advisory panel"}, "#text": "\n              ", "@id": "H957C75D084E4429F80B61614664356E1", "@commented": "no"}, {"#tail": "\n            ", "clause": [{"#tail": "\n              ", "text": {"#tail": "\n              ", "#text": "7 individuals with expertise and experience with clinical diagnostic laboratory tests including expertise in the technical characteristics of the new test as well as expertise in the requirements to develop, validate, and perform the new test;", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(i)"}, "#text": "\n                ", "@id": "H5BDD559A25684724B69B6F99FB58DE18", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n              ", "#text": "3 representatives of patients, including a patient representative for rare disorders;"}, "enum": {"#tail": "\n                ", "#text": "(ii)"}, "#text": "\n                ", "@id": "H787E1DE1FEDD4DC1A14D410AE57C5259", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n              ", "#text": "3 clinicians who use results of the new test in patient care;"}, "enum": {"#tail": "\n                ", "#text": "(iii)"}, "#text": "\n                ", "@id": "H432C95A60E344C3B8520E592D0A76C63", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n              ", "#text": "2 laboratorians;"}, "enum": {"#tail": "\n                ", "#text": "(iv)"}, "#text": "\n                ", "@id": "HF33538BDBCE3430DBD9C7F0D77928814", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n              ", "#text": "2 individuals with expertise in the area of pharmacoeconomics or health technology assessment; and"}, "enum": {"#tail": "\n                ", "#text": "(v)"}, "#text": "\n                ", "@id": "HB49830E2C8BE4469BC47E94D85986A1B", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n              ", "#text": "2 individuals with expertise on the impact of new tests on quality of patient care, including genetic counselors."}, "enum": {"#tail": "\n                ", "#text": "(vi)"}, "#text": "\n                ", "@id": "HD7E58B29436B4E989D82C541661CA21E", "@commented": "no"}], "enum": {"#tail": "\n              ", "#text": "(B)"}, "header": {"#tail": "\n              ", "#text": "Composition of independent advisory panel"}, "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", the independent advisory panel shall be comprised of 19 members, including\u2014", "@entity-type": "act", "#text": "subparagraph (D)", "@value": "MODDERN Cures Act of 2013/s:102/ss:a/p:2/sp:D", "@proposed": "true"}, "#text": "Subject to ", "@display-inline": "yes-display-inline"}, "#text": "\n              ", "@id": "H1C1322E5162A49358C62B04E541C49EC", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", a member of the panel shall be appointed to serve a term of 6 years, except with respect to the members first appointed, whose terms of appointment shall be staggered evenly over 2-year increments.", "@entity-type": "act", "#text": "subparagraph (D)", "@value": "MODDERN Cures Act of 2013/s:102/ss:a/p:2/sp:D", "@proposed": "true"}, "#text": "Subject to ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(C)"}, "header": {"#tail": "\n              ", "#text": "Terms"}, "#text": "\n              ", "@id": "HDB07F09F8BB14CA790F938DF4A1584CD", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " determines with respect to a new test that there are an insufficient number of members of the panel with expertise with respect to that specific test, the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " may appoint individuals who have expertise pertaining to the new test involved to serve on the panel.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "Insofar as the "}, "enum": {"#tail": "\n              ", "#text": "(D)"}, "header": {"#tail": "\n              ", "#text": "Temporary appointment of experts"}, "#text": "\n              ", "@id": "H5CCC50B47CCB4B8C91396FB6C0BD8324"}, {"#tail": "\n            ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall receive or review the findings and recommendations of the independent advisory panel with respect to the new tests described in ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " involved during a meeting open to the public and provide opportunity for public comment.", "@entity-type": "act", "#text": "subparagraph (A)", "@value": "MODDERN Cures Act of 2013/s:102/ss:a/p:2/sp:A", "@proposed": "true"}], "#text": "The ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(E)"}, "header": {"#tail": "\n              ", "#text": "Open meetings"}, "#text": "\n              ", "@id": "H38A96D07E1D142F58857573450792ED3", "@commented": "no"}, {"#tail": "\n          ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " to consult with appropriate Medicare administrative contractors.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "Nothing in this section shall be construed as affecting the authority of the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(F)"}, "header": {"#tail": "\n              ", "#text": "Clarification of authority of secretary to consult carriers"}, "#text": "\n              ", "@id": "H3E3B38306F0B4B4EADBE69ACB57C9949", "@commented": "no"}], "enum": {"#tail": "\n            ", "#text": "(2)"}, "header": {"#tail": "\n            ", "#text": "Input from patients, clinicians, and technical experts"}, "#text": "\n            ", "@id": "H1F0D02B8B64A471C82BFE3FA7B5D7EF5", "@commented": "no"}, {"#tail": "\n        ", "subparagraph": [{"#tail": "\n            ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall publicly provide a justification for the payment basis and payment rate determination, including a detailed summary of the information submitted to, or obtained by, the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " regarding the factors specified in ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ", such that interested stakeholders can readily understand the Secretary\u2019s rationale for the payment basis and rate determinations.", "@entity-type": "act", "#text": "paragraph (1)", "@value": "MODDERN Cures Act of 2013/s:102/ss:a/p:1", "@proposed": "true"}], "#text": "With respect to decisions regarding payments made under the clinical laboratory fee schedule for new clinical diagnostic laboratory tests, the "}, "enum": {"#tail": "\n              ", "#text": "(A)"}, "header": {"#tail": "\n              ", "#text": "Initial justification"}, "#text": "\n              ", "@id": "HDD1B74DC02784A33BEA2D0F0A0BA04C0"}, {"#tail": "\n            ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall provide for a reasonable period of reconsideration to receive any appeal of the determination and to evaluate any additional information received regarding the justification and the factors specified in ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ".", "@entity-type": "act", "#text": "paragraph (1)", "@value": "MODDERN Cures Act of 2013/s:102/ss:a/p:1", "@proposed": "true"}], "#text": "After providing such justification for a payment basis and payment rate determination, the "}, "enum": {"#tail": "\n              ", "#text": "(B)"}, "header": {"#tail": "\n              ", "#text": "Reconsideration period"}, "#text": "\n              ", "@id": "HE2C5E41C70604466B9B83D2367FA2110"}, {"#tail": "\n          ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall make a final payment basis and payment rate determination and provide a justification for such final determination explaining what additional information was evaluated during the reconsideration and how such information was taken into account with respect to the final determination. Nothing in this paragraph shall be construed as authorizing the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " to reveal proprietary information which is otherwise prohibited from disclosure under law.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "After the period of reconsideration the "}, "enum": {"#tail": "\n              ", "#text": "(C)"}, "header": {"#tail": "\n              ", "#text": "Final determination"}, "#text": "\n              ", "@id": "H36520B77F0404D5AAE0EBF347AB4DE36"}], "enum": {"#tail": "\n            ", "#text": "(3)"}, "header": {"#tail": "\n            ", "#text": "Justification for payment determinations"}, "#text": "\n            ", "@id": "HB8E168CEB48246248C5E39AA259525FA"}], "#text": "\n          ", "@id": "H3D2BEA5450D04959BCD9638064BC85D8", "@commented": "no"}, {"#tail": "\n        ", "text": {"#tail": "\n        ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall establish a process for application for the assignment of a temporary national HCPCS code to uniquely identify a diagnostic test until a permanent national HCPCS code is available for assignment to that test. Assignments of a temporary national HCPCS code shall occur on a quarterly basis. The ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " shall provide public notice through the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " Web site of applications made for such temporary national HCPCS codes. Upon assignment of a temporary code under this process, the ", "@entity-type": "federal-body", "#text": "Centers for Medicare & Medicaid Services", "@entity-id": "7530"}, {"#tail": " shall treat such test as a new test for purposes of ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ".", "@entity-type": "act", "#text": "section 1833(h)(8) of the Social Security Act", "@value": "Social Security Act/s:1833/ss:h/p:8"}], "#text": "The ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(b)"}, "header": {"#tail": "\n          ", "#text": "Process for assignment of temporary codes for diagnostic tests"}, "#text": "\n          ", "@id": "HEF8930091096461DB37337835A7103F1", "@commented": "no"}, {"#tail": "\n        ", "text": {"#tail": "\n        ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall analyze the process used for the gapfilling procedure used in determining payment amounts for new clinical diagnostic laboratory tests under ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ". Taking into account the changes made by this section, the ", "@entity-type": "act", "#text": "section 1833(h)(8) of the Social Security Act", "@value": "Social Security Act/s:1833/ss:h/p:8"}, {"#tail": " shall identify further changes to improve the accuracy and appropriateness of resulting rates and the openness, transparency, and predictability of the process. The ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " shall examine what and how many entities should perform gapfilling, under contract or otherwise, and how to ensure that the process is informed by appropriate expertise and proceeds in a transparent and accountable manner. The ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " shall implement improvements in the process, insofar as these are possible under the law through regulations, after public notice and opportunity for comment. For changes the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " determines would require a change in law, the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " shall transmit recommendations to the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " and the ", "@entity-parent-id": "0050", "@entity-type": "federal-body", "#text": "Speaker of the House", "@value": "Speaker of the House"}, {"#tail": " not later than July 1, 2014.", "@entity-parent-id": "0010", "@entity-type": "federal-body", "#text": "President of the Senate", "@value": "President of the Senate"}], "#text": "The ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(c)"}, "header": {"#tail": "\n          ", "#text": "Development of further improvements in rate-Setting processes"}, "#text": "\n          ", "@id": "H76997FFE72B44DF88272A3FBC30B3247", "@commented": "no"}, {"#tail": "\n        ", "text": {"#tail": "\n          ", "#text": "For purposes of this section:", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(d)"}, "header": {"#tail": "\n          ", "#text": "Definitions"}, "paragraph": [{"#tail": "\n          ", "@id": "H8F44FFC2DA6A4DA2B2A43A41BF140962", "enum": {"#tail": "\n            ", "#text": "(1)"}, "header": {"#tail": "\n            ", "#text": "New clinical diagnostic laboratory tests"}, "text": {"#tail": "\n            ", "term": {"#tail": " means a clinical diagnostic laboratory test\u2014", "#text": "new clinical diagnostic laboratory test"}, "#text": "The term ", "@display-inline": "yes-display-inline"}, "#text": "\n            ", "subparagraph": [{"#tail": "\n            ", "text": {"#tail": "\n            ", "#text": "that is assigned a new or substantially revised code on or after January 1, 2013; or"}, "enum": {"#tail": "\n              ", "#text": "(A)"}, "@id": "H0CF396CD0ACD47D7BEC1BD3154DAC447", "#text": "\n              "}, {"#tail": "\n          ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " on or after January 1, 2014.", "@entity-type": "act", "#text": "subsection (b)", "@value": "MODDERN Cures Act of 2013/s:102/ss:b", "@proposed": "true"}, "#text": "for which a temporary national HCPCS code is granted under "}, "enum": {"#tail": "\n              ", "#text": "(B)"}, "@id": "H9D164CEA38EC4FBF8F5CCF4830DB5FA2", "#text": "\n              "}]}, {"#tail": "\n        ", "text": {"#tail": "\n          ", "term": {"#tail": " means, with respect to a health care item or service, an individual who pays out of pocket for such item or service and who does not have health insurance coverage for such item or service.", "#text": "self-pay patient"}, "#text": "The term "}, "enum": {"#tail": "\n            ", "#text": "(2)"}, "header": {"#tail": "\n            ", "#text": "Self-pay patient"}, "#text": "\n            ", "@id": "H32F510813E8344EA97C74687666FCC9A"}], "#text": "\n          ", "@id": "H6E0340E7C766429BADEAA119E1241045"}, {"#tail": "\n      ", "enum": {"#tail": "\n          ", "#text": "(e)"}, "header": {"#tail": "\n          ", "#text": "Effective date"}, "paragraph": [{"#tail": "\n          ", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", this section shall take effect on the date of enactment of this Act and shall apply with respect to new clinical diagnostic laboratory tests.", "@entity-type": "act", "#text": "paragraph (2)", "@value": "MODDERN Cures Act of 2013/s:102/ss:e/p:2", "@proposed": "true"}, "#text": "Subject to "}, "enum": {"#tail": "\n            ", "#text": "(1)"}, "header": {"#tail": "\n            ", "#text": "In general"}, "#text": "\n            ", "@id": "HE63B5DACA4E447A1AAE3CA59012A8E46"}, {"#tail": "\n        ", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall apply to payment basis and payment rate determinations made on or after January 1, 2013.", "@entity-type": "act", "#text": "Subsection (a)(3)", "@value": "MODDERN Cures Act of 2013/s:102/ss:a/p:3", "@proposed": "true"}, "#text": "\n              "}, "enum": {"#tail": "\n            ", "#text": "(2)"}, "header": {"#tail": "\n            ", "#text": "Application of justifications to current rate determinations"}, "#text": "\n            ", "@id": "H3B761FC81E53420FBC24CF4D53B9C99B"}], "#text": "\n          ", "@id": "HE8AE0D19A4554697B8579C8CAAA6B9D7", "@commented": "no"}], "#text": "\n        ", "@id": "H58BA5B094D8A46EBBEF2E7B3AC3344C2", "@commented": "no"}, {"#tail": "\n    ", "enum": {"#tail": "\n        ", "#text": "103."}, "header": {"#tail": "\n        ", "#text": "Promoting the development of innovative diagnostics"}, "subsection": [{"#tail": "\n        ", "enum": {"#tail": "\n          ", "#text": "(a)"}, "header": {"#tail": "\n          ", "#text": "Determination"}, "paragraph": [{"#tail": "\n          ", "@id": "H1A15215933074B89BC4611262046C5A6", "enum": {"#tail": "\n            ", "#text": "(1)"}, "header": {"#tail": "\n            ", "#text": "Request"}, "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " to determine that\u2014", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "The manufacturer or sponsor of a medicine may request the ", "@display-inline": "yes-display-inline"}, "#text": "\n            ", "subparagraph": [{"#tail": "\n            ", "text": {"#tail": "\n            ", "#text": "a diagnostic test has been developed by, or with the participation of, the manufacturer or sponsor of the medicine; and"}, "enum": {"#tail": "\n              ", "#text": "(A)"}, "@id": "H4931841E026D43E8B43C760879916140", "#text": "\n              "}, {"#tail": "\n          ", "text": {"#tail": "\n              ", "#text": "use of the diagnostic test, as demonstrated through valid scientific information such as peer-reviewed literature\u2014"}, "enum": {"#tail": "\n              ", "#text": "(B)"}, "clause": [{"#tail": "\n              ", "text": {"#tail": "\n              ", "#text": "provides for or improves the identification of a patient population for which the medicine will or will not be used in accordance with its approved indications;"}, "enum": {"#tail": "\n                ", "#text": "(i)"}, "@id": "H6012FC4978DB45E0883BDA19E3AEF65F", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n              ", "#text": "provides for or improves the determination of the most appropriate treatment option for a patient population with the medicine in accordance with its approved indications; or", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(ii)"}, "@id": "H5FB01DCFEB694FBC84CB7636445E28DD", "#text": "\n                "}, {"#tail": "\n            ", "text": {"#tail": "\n              ", "#text": "provides for the detection of a qualifying pathogen (as defined in ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": ".", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 505E(f) of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505E/ss:f"}, "@entity-type": "law-citation", "#text": "\n                    ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                    ", "@entity-type": "uscode", "#text": "21 U.S.C. 355(f)", "@value": "usc/21/355/f"}, "@parsable-cite": "usc/21/355", "#text": "\n                      ", "@legal-doc": "usc"}}, "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(iii)"}, "@id": "HC1FC564E11D5474FA897B55EB6C60E0C", "#text": "\n                "}], "#text": "\n              ", "@id": "HC1891BD12FB4469C80B3AA2B2E34D34A"}]}, {"#tail": "\n        ", "@id": "H86FF58678121480889F14BD05CBEAEB9", "enum": {"#tail": "\n            ", "#text": "(2)"}, "header": {"#tail": "\n            ", "#text": "Response by Secretary"}, "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", the ", "@entity-type": "act", "#text": "paragraph (1)", "@value": "MODDERN Cures Act of 2013/s:103/ss:a/p:1", "@proposed": "true"}, {"#tail": ", shall\u2014", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "Not later than 30 days after the submission of a request under "}, "#text": "\n            ", "subparagraph": [{"#tail": "\n            ", "text": {"#tail": "\n            ", "#text": "make the requested determination and publish a notice of such determination and any extension under this section resulting from such determination; or", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(A)"}, "@id": "H3CD3EE84485644499E9DCA2FA8A06B99", "#text": "\n              "}, {"#tail": "\n          ", "text": {"#tail": "\n            ", "#text": "provide an explanation to the manufacturer or sponsor submitting the request of why the determination is not warranted."}, "enum": {"#tail": "\n              ", "#text": "(B)"}, "@id": "HD5EEEEFA69C94C07ABE891795A4AB050", "#text": "\n              "}]}], "@display-inline": "no-display-inline", "#text": "\n          ", "@id": "H54F1D09E19C0401881D8CFAA0B72B14F", "@commented": "no"}, {"#tail": "\n        ", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " and ", "@entity-type": "act", "#text": "subsections (c)", "@value": "MODDERN Cures Act of 2013/s:103/ss:c", "@proposed": "true"}, {"#tail": ", the applicable extension period is\u2014", "@entity-type": "act", "#text": "(d)", "@value": "MODDERN Cures Act of 2013/s:103/ss:d", "@proposed": "true"}], "#text": "For purposes of "}, "enum": {"#tail": "\n          ", "#text": "(b)"}, "header": {"#tail": "\n          ", "#text": "Applicable extension period"}, "paragraph": [{"#tail": "\n          ", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ") contemporaneously with the development of the medicine involved, 12 months; and", "@entity-type": "act", "#text": "subsection (a)(1)(A)", "@value": "MODDERN Cures Act of 2013/s:103/ss:a/p:1/sp:A", "@proposed": "true"}, "#text": "with respect to a diagnostic test developed (as described in "}, "enum": {"#tail": "\n            ", "#text": "(1)"}, "@id": "HEB42F129510841DBAEA7E1EF3031203F", "#text": "\n            "}, {"#tail": "\n        ", "text": {"#tail": "\n          ", "#text": "with respect to a diagnostic test developed otherwise, 6 months."}, "enum": {"#tail": "\n            ", "#text": "(2)"}, "@id": "HE533D05D87814E959696F77E6834FF8C", "#text": "\n            "}], "#text": "\n          ", "@id": "HA05A2DA1BD4748388FFDAC25C4B87968"}, {"#tail": "\n        ", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " makes the determination described in ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " with respect to such drug and a diagnostic test, then\u2014", "@entity-type": "act", "#text": "subsection (a)(1)", "@value": "MODDERN Cures Act of 2013/s:103/ss:a/p:1", "@proposed": "true"}], "#text": "If, at the request of the manufacturer or sponsor of a drug, the "}, "enum": {"#tail": "\n          ", "#text": "(c)"}, "header": {"#tail": "\n          ", "#text": "Extension for drugs"}, "paragraph": [{"#tail": "\n          ", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " and ", "@entity-type": "act", "#text": "clauses (iii)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:c/p:3/sp:E/cl:iii"}, {"#tail": " and ", "@entity-type": "act", "#text": "(iv) of subsection (c)(3)(E)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:c/p:3/sp:E/cl:iv"}, {"#tail": " and ", "@entity-type": "act", "#text": "clauses (iii)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:F/cl:iii"}, {"#tail": ", or the seven-year period described in ", "@entity-type": "act", "#text": "(iv) of subsection (j)(5)(F) of such section 505", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:F/cl:iv"}], "#text": "the four- and five-year periods described in ", "{http://namespaces.cato.org/catoxml}entity": [{"#tail": ", the three-year periods described in ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " and ", "@entity-type": "act", "#text": "subsections (c)(3)(E)(ii)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:c/p:3/sp:E/cl:ii"}, {"#tail": " (", "@entity-type": "act", "#text": "(j)(5)(F)(ii) of section 505 of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:F/cl:ii"}], "@entity-type": "law-citation", "#text": "\n                ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                ", "@entity-type": "uscode", "#text": "21 U.S.C. 355", "@value": "usc/21/355"}, "@parsable-cite": "usc/21/355", "#text": "\n                  ", "@legal-doc": "usc"}}, {"#tail": ", as applicable, shall be extended by the applicable extension period;", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 527 of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:527"}, "@entity-type": "law-citation", "#text": "\n                ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                ", "@entity-type": "uscode", "#text": "21 U.S.C. 360cc", "@value": "usc/21/360cc"}, "@parsable-cite": "usc/21/360cc", "#text": "\n                  ", "@legal-doc": "usc"}}], "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n            ", "#text": "(1)"}, "#text": "\n            ", "@id": "H0783BE323CCE4EEC8F9B11768F307909", "@commented": "no"}, {"continuation-text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " or ", "@entity-type": "act", "#text": "subsection (c)(3)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:c/p:3"}, {"#tail": " shall be extended by the applicable extension period after the date the patent expires (including any patent extensions); and", "@entity-type": "act", "#text": "(j)(5)(B) of such section 505", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:B"}], "@continuation-text-level": "paragraph", "#text": "then the period during which an application may not be approved under ", "@commented": "no"}, "#tail": "\n          ", "text": {"#tail": "\n            ", "#text": "if the drug is the subject of\u2014"}, "enum": {"#tail": "\n            ", "#text": "(2)"}, "#text": "\n            ", "@id": "H9618E8A0C20C44BCB2CC226D61505872", "@commented": "no", "subparagraph": [{"#tail": "\n            ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " or ", "@entity-type": "act", "#text": "subsection (b)(2)(A)(ii)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:b/p:2/sp:A/cl:ii"}, {"#tail": "; or", "@entity-type": "act", "#text": "(j)(2)(A)(vii)(II) of such section 505", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:2/sp:A/cl:vii/scl:II"}], "#text": "a listed patent for which a certification has been submitted under "}, "enum": {"#tail": "\n              ", "#text": "(A)"}, "#text": "\n              ", "@id": "H4D2B2969365D4D6EACA415797B672722", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " or ", "@entity-type": "act", "#text": "subsection (b)(2)(A)(iii)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:b/p:2/sp:A/cl:iii"}, {"#tail": ",", "@entity-type": "act", "#text": "(j)(2)(A)(vii)(III) of such section 505", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:2/sp:A/cl:vii/scl:III"}], "#text": "a listed patent for which a certification has been submitted under "}, "enum": {"#tail": "\n              ", "#text": "(B)"}, "#text": "\n              ", "@id": "HA54B3D6883C0472FA3D7E282454AD741", "@commented": "no"}]}, {"#tail": "\n        ", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " or ", "@entity-type": "act", "#text": "subsection (b)(2)(A)(iv)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:b/p:2/sp:A/cl:iv"}, {"#tail": ", and in the patent infringement litigation resulting from the certification the court determines that the patent is valid and would be infringed, the period during which an application may not be approved under ", "@entity-type": "act", "#text": "(j)(2)(A)(vii)(IV) of such section 505", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:2/sp:A/cl:vii/scl:IV"}, {"#tail": " or ", "@entity-type": "act", "#text": "subsection (c)(3)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:c/p:3"}, {"#tail": " shall be extended by the applicable extension period after the date the patent expires (including any patent extension).", "@entity-type": "act", "#text": "(j)(5)(B) of such section 505", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:B"}], "#text": "if the drug is the subject of a listed patent for which a certification has been submitted under "}, "enum": {"#tail": "\n            ", "#text": "(3)"}, "#text": "\n            ", "@id": "H1D4851BAF88B4CEEA4955A1CB023D047", "@commented": "no"}], "#text": "\n          ", "@id": "HC5D9CB7029D7477DB94F7F4F00FF7078", "@commented": "no"}, {"#tail": "\n        ", "text": {"#tail": "\n        ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " makes the determination described in ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " with respect to such biological product and a diagnostic test, then the 12-year period described in ", "@entity-type": "act", "#text": "subsection (a)(1)", "@value": "MODDERN Cures Act of 2013/s:103/ss:a/p:1", "@proposed": "true"}, {"#tail": ", and the 7-year period described in ", "@entity-type": "act", "#text": "subsection (k)(7)(B) of such section 351", "@value": "Public Health Service Act/s:351/ss:k/p:7/sp:B"}], "#text": "If, at the request of the manufacturer or sponsor of a biological product, the ", "{http://namespaces.cato.org/catoxml}entity": [{"#tail": ", the 4-year period described in ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "subsection (k)(7)(A) of section 351 of the Public Health Service Act", "@value": "Public Health Service Act/s:351/ss:k/p:7/sp:A"}, "@entity-type": "law-citation", "#text": "\n              ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n              ", "@entity-type": "uscode", "#text": "42 U.S.C. 262", "@value": "usc/42/262"}, "@parsable-cite": "usc/42/262", "#text": "\n                ", "@legal-doc": "usc"}}, {"#tail": ", as applicable, shall be extended by the applicable extension period.", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 527 of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:527"}, "@entity-type": "law-citation", "#text": "\n              ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n              ", "@entity-type": "uscode", "#text": "21 U.S.C. 360cc", "@value": "usc/21/360cc"}, "@parsable-cite": "usc/21/360cc", "#text": "\n                ", "@legal-doc": "usc"}}], "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(d)"}, "header": {"#tail": "\n          ", "#text": "Extension for biological products"}, "#text": "\n          ", "@id": "H1A8DE57C8B624ED38EBAA9C1DCD19A07"}, {"#tail": "\n        ", "text": {"#tail": "\n        ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " or ", "@entity-type": "act", "#text": "subsection (c)", "@value": "MODDERN Cures Act of 2013/s:103/ss:c", "@proposed": "true"}, {"#tail": " of a period shall be in addition to any extension of the period under ", "@entity-type": "act", "#text": "(d)", "@value": "MODDERN Cures Act of 2013/s:103/ss:d", "@proposed": "true"}], "#text": "Any extension under ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " with respect to the medicine.", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 505A of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505A"}, "@entity-type": "law-citation", "#text": "\n              ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n              ", "@entity-type": "uscode", "#text": "21 U.S.C. 355a", "@value": "usc/21/355a"}, "@parsable-cite": "usc/21/355a", "#text": "\n                ", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n          ", "#text": "(e)"}, "header": {"#tail": "\n          ", "#text": "Relation to pediatric exclusivity"}, "@display-inline": "no-display-inline", "#text": "\n          ", "@id": "H534BD73988154B2D84CF486D4C8DEC1B"}, {"#tail": "\n      ", "text": {"#tail": "\n          ", "#text": "Extensions under this section may apply\u2014", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(f)"}, "header": {"#tail": "\n          ", "#text": "Limitations"}, "paragraph": [{"#tail": "\n          ", "text": {"#tail": "\n          ", "#text": "not more than twice with respect to the same medicine; and"}, "enum": {"#tail": "\n            ", "#text": "(1)"}, "@id": "H8FE4CF8A9CDF400DA4D8AE51F326506A", "#text": "\n            "}, {"#tail": "\n        ", "text": {"#tail": "\n          ", "#text": "not more than once with respect to the same indication to be treated by the same medicine."}, "enum": {"#tail": "\n            ", "#text": "(2)"}, "@id": "H8E59FC13106A480387517FA5D38F1850", "#text": "\n            "}], "#text": "\n          ", "@id": "H77E749F9F55F481C96C071BDFCE6F52E"}], "#text": "\n        ", "@id": "HDA8CEFDCAAC449B88CAFEE4F3EFE0AB3"}], "enum": {"#tail": "\n      ", "#text": "I"}, "header": {"#tail": "\n      ", "#text": "Advancing diagnostics for patients"}, "#text": "\n      ", "@id": "H24A65B9C2A16445082C0EE3B3B8A9A35"}, {"#tail": "\n  ", "section": [{"#tail": "\n      ", "enum": {"#tail": "\n        ", "#text": "201."}, "header": {"#tail": "\n        ", "#text": "Dormant therapies"}, "subsection": [{"#tail": "\n        ", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall designate a medicine as a dormant therapy if\u2014", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "The ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(a)"}, "header": {"#tail": "\n          ", "#text": "Designation as dormant therapy"}, "paragraph": [{"#tail": "\n          ", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", and the request has not been withdrawn under ", "@entity-type": "act", "#text": "subsection (b)", "@value": "MODDERN Cures Act of 2013/s:201/ss:b", "@proposed": "true"}, {"#tail": "; and", "@entity-type": "act", "#text": "subsection (d)(1)", "@value": "MODDERN Cures Act of 2013/s:201/ss:d/p:1", "@proposed": "true"}], "#text": "the sponsor of the medicine submits a request for such designation meeting the requirements under "}, "enum": {"#tail": "\n            ", "#text": "(1)"}, "@id": "HB08F62D313394C70BF77D698633AD87F", "#text": "\n            "}, {"#tail": "\n        ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " determines that\u2014", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "the "}, "enum": {"#tail": "\n            ", "#text": "(2)"}, "#text": "\n            ", "@id": "H6FAC30E518C4415EBC79A63653851BAF", "subparagraph": [{"#tail": "\n            ", "text": {"#tail": "\n            ", "#text": "the medicine is being investigated or is intended to be investigated for an indication to address one or more unmet medical needs;"}, "enum": {"#tail": "\n              ", "#text": "(A)"}, "@id": "HC3F71A3D35EC499DB29D5478A474D1C4", "#text": "\n              "}, {"#tail": "\n            ", "text": {"#tail": "\n            ", "#text": "a suitable clinical plan for such investigations of the medicine has been developed by the sponsor;"}, "enum": {"#tail": "\n              ", "#text": "(B)"}, "@id": "HAB0F18D03795424D96755AC15CEDABE6", "#text": "\n              "}, {"#tail": "\n            ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "; and", "@entity-type": "act", "#text": "subparagraph (A)", "@value": "MODDERN Cures Act of 2013/s:201/ss:a/p:2/sp:A", "@proposed": "true"}, "#text": "the sponsor intends to file an application pursuant to ", "{http://namespaces.cato.org/catoxml}entity": [{"#tail": " or ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 505(b) of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:b"}, "@entity-type": "law-citation", "#text": "\n                  ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                  ", "@entity-type": "uscode", "#text": "21 U.S.C. 355(b)", "@value": "usc/21/355/b"}, "@parsable-cite": "usc/21/355", "#text": "\n                    ", "@legal-doc": "usc"}}, {"#tail": " for approval or licensing of the medicine for an indication described in ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 351(a) of the Public Health Service Act", "@value": "Public Health Service Act/s:351/ss:a"}, "@entity-type": "law-citation", "#text": "\n                  ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                  ", "@entity-type": "uscode", "#text": "42 U.S.C. 262(a)", "@value": "usc/42/262/a"}, "@parsable-cite": "usc/42/262", "#text": "\n                    ", "@legal-doc": "usc"}}]}, "enum": {"#tail": "\n              ", "#text": "(C)"}, "@id": "HF77DFA6BC85642D99E1F22E1BEC35131", "#text": "\n              "}, {"#tail": "\n          ", "text": {"#tail": "\n            ", "#text": "the request for designation was made on or before the date of submission of any application under ", "{http://namespaces.cato.org/catoxml}entity": [{"#tail": " or ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 505 of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505"}, "@entity-type": "law-citation", "#text": "\n                  ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                  ", "@entity-type": "uscode", "#text": "21 U.S.C. 355", "@value": "usc/21/355"}, "@parsable-cite": "usc/21/355", "#text": "\n                    ", "@legal-doc": "usc"}}, {"#tail": " for the approval or licensure of commercial marketing or use of a medicine that in the case of a drug shares an active moiety that is the same as, and in the case of a biologic contains an active moiety that is highly similar to, an active moiety in the medicine for which designation is being requested.", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 351 of the Public Health Service Act", "@value": "Public Health Service Act/s:351"}, "@entity-type": "law-citation", "#text": "\n                  ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                  ", "@entity-type": "uscode", "#text": "42 U.S.C. 262", "@value": "usc/42/262"}, "@parsable-cite": "usc/42/262", "#text": "\n                    ", "@legal-doc": "usc"}}], "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(D)"}, "@id": "HD901EBB9FC46409A89D5FAC8964FD9CE", "#text": "\n              "}]}], "#text": "\n          ", "@id": "H5D03BA7606C74BF582E6622067D0A486"}, {"#tail": "\n        ", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " with respect to a medicine may only be made by the sponsor of the medicine and shall contain each of the following:", "@entity-type": "act", "#text": "subsection (a)(1)", "@value": "MODDERN Cures Act of 2013/s:201/ss:a/p:1", "@proposed": "true"}, "#text": "A request under "}, "enum": {"#tail": "\n          ", "#text": "(b)"}, "header": {"#tail": "\n          ", "#text": "Requirements for request for designation as dormant therapy"}, "paragraph": [{"#tail": "\n          ", "text": {"#tail": "\n          ", "#text": "A listing of all patents and applications for patents under which the sponsor has rights and that may be reasonably construed to provide protection for the medicine."}, "enum": {"#tail": "\n            ", "#text": "(1)"}, "@id": "H0021AE82308845A1BF4F15C482A5D232", "#text": "\n            "}, {"#tail": "\n          ", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " to take effect, if at all, as provided under ", "@entity-type": "act", "#text": "subsection (c)", "@value": "MODDERN Cures Act of 2013/s:201/ss:c", "@proposed": "true"}, {"#tail": ".", "@entity-type": "act", "#text": "subsection (c)(3)", "@value": "MODDERN Cures Act of 2013/s:201/ss:c/p:3", "@proposed": "true"}], "#text": "A waiver of patent rights to the extent required under "}, "enum": {"#tail": "\n            ", "#text": "(2)"}, "@id": "H5333EA8281C04D84B91AA918942D58D6", "#text": "\n            "}, {"#tail": "\n        ", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " may require by regulation in order to determine eligibility for designation under ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ".", "@entity-type": "act", "#text": "subsection (a)", "@value": "MODDERN Cures Act of 2013/s:201/ss:a", "@proposed": "true"}], "#text": "Such additional information as the "}, "enum": {"#tail": "\n            ", "#text": "(3)"}, "@id": "H976352007C21476BABC5433C7840C57F", "#text": "\n            "}], "#text": "\n          ", "@id": "H1DF16E401EEA4F94B97537383298367F"}, {"#tail": "\n        ", "enum": {"#tail": "\n          ", "#text": "(c)"}, "header": {"#tail": "\n          ", "#text": "Waiver of patent rights expiring after the protection period ends"}, "paragraph": [{"#tail": "\n          ", "subparagraph": [{"#tail": "\n            ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", the request under this subsection shall include a waiver of the right to enforce or otherwise assert any patent described in ", "@entity-type": "act", "#text": "subparagraph (B)", "@value": "MODDERN Cures Act of 2013/s:201/ss:c/p:1/sp:B", "@proposed": "true"}, {"#tail": " (or any patent issued on the basis of an application described in ", "@entity-type": "act", "#text": "subsection (b)(1)", "@value": "MODDERN Cures Act of 2013/s:201/ss:b/p:1", "@proposed": "true"}, {"#tail": "), which may expire after the end of the protection period for the dormant therapy, against any applicable product described in ", "@entity-type": "act", "#text": "subsection (b)(1)", "@value": "MODDERN Cures Act of 2013/s:201/ss:b/p:1", "@proposed": "true"}, {"#tail": ". The waiver shall be made by the owner of the patent or application for patent, as the case may be.", "@entity-type": "act", "#text": "paragraph (2)", "@value": "MODDERN Cures Act of 2013/s:201/ss:c/p:2", "@proposed": "true"}], "#text": "Subject to ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(A)"}, "header": {"#tail": "\n              ", "#text": "In general"}, "#text": "\n              ", "@id": "HF038465311E54FB7A85DCE78576C6656"}, {"#tail": "\n          ", "clause": [{"#tail": "\n              ", "text": {"#tail": "\n              ", "#text": "shall have no effect during the protection period for the medicine to which the waiver relates; and"}, "enum": {"#tail": "\n                ", "#text": "(i)"}, "@id": "H348029A3D6BE46EAB8C4EEB5A16BCCD2", "#text": "\n                "}, {"#tail": "\n            ", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "act", "#text": "paragraph (2)", "@value": "MODDERN Cures Act of 2013/s:201/ss:c/p:2", "@proposed": "true"}, "#text": "shall have no effect with respect to the subject matter of a claimed invention in a patent that does not provide any protection for such medicine with respect to an applicable product described in "}, "enum": {"#tail": "\n                ", "#text": "(ii)"}, "@id": "H8525D540ADCD4EC59B78621A331CB55B", "#text": "\n                "}], "enum": {"#tail": "\n              ", "#text": "(B)"}, "header": {"#tail": "\n              ", "#text": "Limitations on patent waiver"}, "text": {"#tail": "\n              ", "#text": "Any patent waiver provided pursuant to this section, should it become effective\u2014"}, "#text": "\n              ", "@id": "H025ABF6626D746F198FF41F931C5B24C"}], "enum": {"#tail": "\n            ", "#text": "(1)"}, "header": {"#tail": "\n            ", "#text": "Patent waiver"}, "#text": "\n            ", "@id": "H2099B24725E24C268E0CD10788B30C07"}, {"#tail": "\n          ", "@id": "HD4F55149679F4223A2B2F178806436C0", "enum": {"#tail": "\n            ", "#text": "(2)"}, "header": {"#tail": "\n            ", "#text": "Applicable products described"}, "text": {"#tail": "\n            ", "#text": "An applicable product is described in this paragraph only if\u2014"}, "#text": "\n            ", "subparagraph": [{"#tail": "\n            ", "text": {"#tail": "\n              ", "#text": "it is approved or licensed pursuant to an application that\u2014"}, "enum": {"#tail": "\n              ", "#text": "(A)"}, "clause": [{"#tail": "\n              ", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " or ", "@entity-type": "act", "#text": "section 505(b)(2)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:b/p:2"}, {"#tail": " (", "@entity-type": "act", "#text": "505(j) of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:j"}, {"#tail": ") or ", "@entity-type": "uscode", "#text": "(j)", "@value": "usc/21/355/j"}], "#text": "is filed under \n                    ", "external-xref": {"#tail": ", ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                    ", "@entity-type": "uscode", "#text": "21 U.S.C. 355(b)(2)", "@value": "usc/21/355/b/2"}, "@parsable-cite": "usc/21/355", "#text": "\n                      ", "@legal-doc": "usc"}, "{http://namespaces.cato.org/catoxml}entity": {"#tail": "; and", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 351(k) of the Public Health Service Act", "@value": "Public Health Service Act/s:351/ss:k"}, "@entity-type": "law-citation", "#text": "\n                    ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                    ", "@entity-type": "uscode", "#text": "42 U.S.C. 262(k)", "@value": "usc/42/262/k"}, "@parsable-cite": "usc/42/262", "#text": "\n                      ", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n                ", "#text": "(i)"}, "@id": "H5A2E1D9A9D7B47A6BA9E0E61883B8EC2", "#text": "\n                "}, {"#tail": "\n            ", "text": {"#tail": "\n              ", "#text": "references or otherwise relies upon the approval or licensure of the dormant therapy to which the waiver relates; and"}, "enum": {"#tail": "\n                ", "#text": "(ii)"}, "@id": "H663CDF259ACC4F79BF57603F5A87F8D6", "#text": "\n                "}], "#text": "\n              ", "@id": "H68B2F8B3E77D4A9C957F90E0F3599F70"}, {"#tail": "\n          ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " relates.", "@entity-type": "act", "#text": "subsection (a)(1)", "@value": "MODDERN Cures Act of 2013/s:201/ss:a/p:1", "@proposed": "true"}, "#text": "the approval of the product occurs after the expiration of the protection period applicable to the medicine to which the request under "}, "enum": {"#tail": "\n              ", "#text": "(B)"}, "@id": "HDE689FCC5DE64D3E8267D9D2C6DD9864", "#text": "\n              "}]}, {"#tail": "\n        ", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " with respect to a patent shall take effect, if at all, on the date the ", "@entity-type": "act", "#text": "subsection (b)(2)", "@value": "MODDERN Cures Act of 2013/s:201/ss:b/p:2", "@proposed": "true"}, {"#tail": " publishes the notice required under ", "@entity-type": "federal-body", "#text": "Director", "@entity-id": "1344"}, {"#tail": " relating to the patent.", "@entity-type": "act", "#text": "subsection (e)(2)(F)", "@value": "MODDERN Cures Act of 2013/s:201/ss:e/p:2/sp:F", "@proposed": "true"}], "#text": "A waiver under ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n            ", "#text": "(3)"}, "header": {"#tail": "\n            ", "#text": "Effective date of waiver"}, "#text": "\n            ", "@id": "H67AC12934A9549F1A07B61165BD8AB33"}], "#text": "\n          ", "@id": "H7465AF6F354D45639180246ED3032C35"}, {"#tail": "\n        ", "enum": {"#tail": "\n          ", "#text": "(d)"}, "header": {"#tail": "\n          ", "#text": "Withdrawal of request for designation, revocation by the secretary"}, "paragraph": [{"#tail": "\n          ", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " with respect to a medicine unless the medicine has been approved or licensed under ", "@entity-type": "act", "#text": "subsection (a)(1)", "@value": "MODDERN Cures Act of 2013/s:201/ss:a/p:1", "@proposed": "true"}, {"#tail": " shall deny a designation request or revoke any designation granted if at any time the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " finds that the sponsor is not in compliance with ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " and ", "@entity-type": "act", "#text": "subsections (c)(1)", "@value": "MODDERN Cures Act of 2013/s:201/ss:c/p:1", "@proposed": "true"}, {"#tail": ".", "@entity-type": "act", "#text": "(g)(1)", "@value": "MODDERN Cures Act of 2013/s:201/ss:g/p:1", "@proposed": "true"}], "#text": "The sponsor of a medicine may withdraw a request for designation under ", "{http://namespaces.cato.org/catoxml}entity": [{"#tail": " or ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 505 of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505"}, "@entity-type": "law-citation", "#text": "\n                ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                ", "@entity-type": "uscode", "#text": "21 U.S.C. 355", "@value": "usc/21/355"}, "@parsable-cite": "usc/21/355", "#text": "\n                  ", "@legal-doc": "usc"}}, {"#tail": ". The ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 351 of the Public Health Service Act", "@value": "Public Health Service Act/s:351"}, "@entity-type": "law-citation", "#text": "\n                ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                ", "@entity-type": "uscode", "#text": "42 U.S.C. 262", "@value": "usc/42/262"}, "@parsable-cite": "usc/42/262", "#text": "\n                  ", "@legal-doc": "usc"}}]}, "enum": {"#tail": "\n            ", "#text": "(1)"}, "header": {"#tail": "\n            ", "#text": "In general"}, "#text": "\n            ", "@id": "HCD01B0CE6C4344008D2219CBD7F02D75"}, {"#tail": "\n          ", "@id": "HEFAD27D2DEA7440C9D44BCC2528B2E24", "enum": {"#tail": "\n            ", "#text": "(2)"}, "header": {"#tail": "\n            ", "#text": "Effects of withdrawal of request or revocation of designation"}, "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " or the ", "@entity-type": "act", "#text": "subsection (b)", "@value": "MODDERN Cures Act of 2013/s:201/ss:b", "@proposed": "true"}, {"#tail": " denies a designation request or revokes a designation with respect to the medicine\u2014", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "If the sponsor of a medicine withdraws a request under "}, "#text": "\n            ", "subparagraph": [{"#tail": "\n            ", "text": {"#tail": "\n            ", "#text": "any patent waiver submitted under this section with respect to the medicine, but not yet effective, is canceled and deemed a nullity;"}, "enum": {"#tail": "\n              ", "#text": "(A)"}, "@id": "HAB7E708288EC48C8B9E38FF492ADDE06", "#text": "\n              "}, {"#tail": "\n            ", "text": {"#tail": "\n            ", "#text": "any patent waiver that has taken effect under this section with respect to the medicine shall remain in effect;"}, "enum": {"#tail": "\n              ", "#text": "(B)"}, "@id": "H96AC7ACA7D7546989E09D5BC60AF8CF0", "#text": "\n              "}, {"#tail": "\n            ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " under ", "@entity-type": "federal-body", "#text": "Director", "@entity-id": "1344"}, {"#tail": " with respect to the medicine shall be canceled, except that the ", "@entity-type": "act", "#text": "subsection (e)(2)", "@value": "MODDERN Cures Act of 2013/s:201/ss:e/p:2", "@proposed": "true"}, {"#tail": " shall maintain the patent term extension for one patent, to be selected by the sponsor of the medicine, for the period of extension that would have been applicable under ", "@entity-type": "federal-body", "#text": "Director", "@entity-id": "1344"}, {"#tail": "; and", "@entity-type": "uscode", "#text": "\n                  ", "external-xref": {"#tail": " of title 35, United States Code", "@parsable-cite": "usc/35/156", "#text": "section 156", "@legal-doc": "usc"}, "@value": "usc/35/156"}], "#text": "any patent term extension granted by the "}, "enum": {"#tail": "\n              ", "#text": "(C)"}, "@id": "H2D16E03CD51C4B93813E64B4DA01AEFD", "#text": "\n              "}, {"#tail": "\n          ", "text": {"#tail": "\n            ", "#text": "the designation, if made, otherwise shall be treated as never having been requested or made or having effect."}, "enum": {"#tail": "\n              ", "#text": "(D)"}, "@id": "H04906A949D4449EFB250CCC227A61D61", "#text": "\n              "}]}, {"#tail": "\n        ", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " may revoke a designation made under ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ", but only based upon a finding by the ", "@entity-type": "act", "#text": "subsection (a)", "@value": "MODDERN Cures Act of 2013/s:201/ss:a", "@proposed": "true"}, {"#tail": " under ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ".", "@entity-type": "act", "#text": "paragraph (1)", "@value": "MODDERN Cures Act of 2013/s:201/ss:d/p:1", "@proposed": "true"}], "#text": "The "}, "enum": {"#tail": "\n            ", "#text": "(3)"}, "header": {"#tail": "\n            ", "#text": "Basis for revocation"}, "#text": "\n            ", "@id": "HBBE0171E16F24FB584B899EC722E0D0B"}], "#text": "\n          ", "@id": "H212E2520DAF144FCA42B7A3D8F90E791"}, {"#tail": "\n        ", "enum": {"#tail": "\n          ", "#text": "(e)"}, "header": {"#tail": "\n          ", "#text": "Guaranteed protections for dormant therapies"}, "paragraph": [{"#tail": "\n          ", "@id": "HDE9859E6CFD344F2BE1F6A0D9833C793", "enum": {"#tail": "\n            ", "#text": "(1)"}, "header": {"#tail": "\n            ", "#text": "Applications filed during the protection period"}, "text": {"#tail": "\n            ", "#text": "During the protection period for a dormant therapy, notwithstanding any other provision of the ", "{http://namespaces.cato.org/catoxml}entity": [{"#tail": " or the ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act"}, "@entity-type": "law-citation", "#text": "\n                ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                ", "@entity-type": "uscode", "#text": "21 U.S.C. 301 et seq.", "@value": "usc/21/301/etseq"}, "@parsable-cite": "usc/21/301", "#text": "\n                  ", "@legal-doc": "usc"}}, {"#tail": "\u2014", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Public Health Service Act", "@value": "Public Health Service Act"}, "@entity-type": "law-citation", "#text": "\n                ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                ", "@entity-type": "uscode", "#text": "42 U.S.C. 201 et seq.", "@value": "usc/42/201/etseq"}, "@parsable-cite": "usc/42/201", "#text": "\n                  ", "@legal-doc": "usc"}}]}, "#text": "\n            ", "subparagraph": [{"#tail": "\n            ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall not approve an application filed pursuant to \n                  ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " or ", "@entity-type": "act", "#text": "section 505(b)(2)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:b/p:2"}, {"#tail": " (", "@entity-type": "act", "#text": "section 505(j) of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:j"}, {"#tail": ") or ", "@entity-type": "uscode", "#text": "(j)", "@value": "usc/21/355/j"}], "#text": "absent a right of reference from the holder of such approved application for the dormant therapy, the ", "external-xref": {"#tail": ", ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                  ", "@entity-type": "uscode", "#text": "21 U.S.C. 355(b)(2)", "@value": "usc/21/355/b/2"}, "@parsable-cite": "usc/21/355", "#text": "\n                    ", "@legal-doc": "usc"}, "{http://namespaces.cato.org/catoxml}entity": {"#tail": " referencing or otherwise relying on the approval or licensure of the dormant therapy;", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 351(k) of the Public Health Service Act", "@value": "Public Health Service Act/s:351/ss:k"}, "@entity-type": "law-citation", "#text": "\n                  ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                  ", "@entity-type": "uscode", "#text": "42 U.S.C. 262(k)", "@value": "usc/42/262/k"}, "@parsable-cite": "usc/42/262", "#text": "\n                    ", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n              ", "#text": "(A)"}, "@id": "H3B5A19E67D834FAEAD6FF1BA2EB6CB72", "#text": "\n              "}, {"#tail": "\n            ", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall not approve\u2014", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "the "}, "enum": {"#tail": "\n              ", "#text": "(B)"}, "clause": [{"#tail": "\n              ", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " or ", "@entity-type": "act", "#text": "section 505(b)(2)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:b/p:2"}, {"#tail": " that references or otherwise relies on the approval or licensure of a medicine that is not the dormant therapy, was approved subsequent to the approval of the dormant therapy, and contains the same active moiety as the active moiety in the dormant therapy (or if the dormant therapy contains more than one active moiety, all of the active moieties are the same); or", "@entity-type": "act", "#text": "505(j)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:j"}], "#text": "an application filed pursuant to such ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(i)"}, "@id": "H5CAB9FE1FAA043CF8B51D64EE8E241D0", "#text": "\n                "}, {"#tail": "\n            ", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " that references or otherwise relies on the approval or licensure of a medicine that is not the dormant therapy, was approved subsequent to the approval or licensure of the dormant therapy, and contains an active moiety that is highly similar to the active moiety in the dormant therapy (or if the dormant therapy contains more than one active moiety, all of the active moieties are highly similar); and", "@entity-type": "act", "#text": "section 351(k)", "@value": "Federal Food, Drug, and Cosmetic Act/s:351/ss:k"}, "#text": "an application filed pursuant to such ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(ii)"}, "@id": "H67287FC29BAE465BB5579A9503D217FD", "#text": "\n                "}], "#text": "\n              ", "@id": "H7215FA9AFE3C41F69082E4EBAE987102"}, {"#tail": "\n          ", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall not approve an application filed pursuant to ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "the ", "{http://namespaces.cato.org/catoxml}entity": [{"#tail": " for a drug that contains the same active moiety as the active moiety in the dormant therapy (or if the dormant therapy contains more than one active moiety, all of the active moieties are the same), or an application filed pursuant to ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:b/p:1"}, "@entity-type": "law-citation", "#text": "\n                  ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                  ", "@entity-type": "uscode", "#text": "21 U.S.C. 355(b)(1)", "@value": "usc/21/355/b/1"}, "@parsable-cite": "usc/21/355", "#text": "\n                    ", "@legal-doc": "usc"}}, {"#tail": " for a biological product that contains an active moiety that is highly similar to the active moiety in the dormant therapy (or if the dormant therapy contains more than one active moiety, all of the active moieties are highly similar), unless\u2014", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 351(a) of the Public Health Service Act", "@value": "Public Health Service Act/s:351/ss:a"}, "@entity-type": "law-citation", "#text": "\n                  ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                  ", "@entity-type": "uscode", "#text": "42 U.S.C. 262(a)", "@value": "usc/42/262/a"}, "@parsable-cite": "usc/42/262", "#text": "\n                    ", "@legal-doc": "usc"}}], "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(C)"}, "clause": [{"#tail": "\n              ", "text": {"#tail": "\n              ", "#text": "the information provided to support approval of such application is comparable in scope and extent, including with respect to design and extent of preclinical and clinical testing, to the information provided to support approval of the application for the dormant therapy under ", "{http://namespaces.cato.org/catoxml}entity": [{"#tail": " or ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 505(b) of the Federal Food, Drug and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:b"}, "@entity-type": "law-citation", "#text": "\n                    ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                    ", "@entity-type": "uscode", "#text": "21 U.S.C. 355(b)", "@value": "usc/21/355/b"}, "@parsable-cite": "usc/21/355", "#text": "\n                      ", "@legal-doc": "usc"}}, {"#tail": "; and", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 351(a) of the Public Health Service Act", "@value": "Public Health Service Act/s:351/ss:a"}, "@entity-type": "law-citation", "#text": "\n                    ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                    ", "@entity-type": "uscode", "#text": "42 U.S.C. 262(a)", "@value": "usc/42/262/a"}, "@parsable-cite": "usc/42/262", "#text": "\n                      ", "@legal-doc": "usc"}}]}, "enum": {"#tail": "\n                ", "#text": "(i)"}, "@id": "H60D7476407B041E5A33A721A12AA7D36", "#text": "\n                "}, {"#tail": "\n            ", "text": {"#tail": "\n                ", "#text": "if such clinical testing had not commenced before the approval of the application for the dormant therapy, the clinical testing establishes clinical superiority in the form of a significant therapeutic advantage over and above that provided by the dormant therapy in one or more of the following ways:"}, "enum": {"#tail": "\n                ", "#text": "(ii)"}, "subclause": [{"#tail": "\n                ", "text": {"#tail": "\n                ", "#text": "Greater effectiveness on a clinically meaningful endpoint."}, "enum": {"#tail": "\n                  ", "#text": "(I)"}, "@id": "H1E7E87D287CD4C89B451803760D6DE66", "#text": "\n                  "}, {"#tail": "\n                ", "text": {"#tail": "\n                ", "#text": "Greater safety in a substantial portion of the target populations."}, "enum": {"#tail": "\n                  ", "#text": "(II)"}, "@id": "H893F5A584AF54704A64D3222398B10D1", "#text": "\n                  "}, {"#tail": "\n              ", "text": {"#tail": "\n                ", "#text": "Where neither greater safety nor greater effectiveness has been shown, a demonstration that the drug otherwise makes a major contribution to patient care."}, "enum": {"#tail": "\n                  ", "#text": "(III)"}, "@id": "H028AF0C5A50F4878B2DC19AF1AABF783", "#text": "\n                  "}], "#text": "\n                ", "@id": "HF733219FFAB24A889C93A2EF147E34B9"}], "#text": "\n              ", "@id": "H23EDCDADF0FA40938F9FBA4D609BDC6F"}]}, {"#tail": "\n        ", "subparagraph": [{"#tail": "\n            ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", a sponsor of a medicine designated as a dormant therapy under ", "@entity-type": "uscode", "#text": "title 35, United States Code", "@value": "usc/35"}, {"#tail": ", upon the approval or licensure thereof under ", "@entity-type": "act", "#text": "subsection (a)(1)", "@value": "MODDERN Cures Act of 2013/s:201/ss:a/p:1", "@proposed": "true"}, {"#tail": ", shall be entitled to patent term extensions in accordance with this paragraph.", "@entity-type": "uscode", "#text": "section 156(d) of such title 35", "@value": "usc/35/156/d"}], "#text": "Notwithstanding any provision of ", "{http://namespaces.cato.org/catoxml}entity": [{"#tail": " or ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 505 of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505"}, "@entity-type": "law-citation", "#text": "\n                  ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                  ", "@entity-type": "uscode", "#text": "21 U.S.C. 355", "@value": "usc/21/355"}, "@parsable-cite": "usc/21/355", "#text": "\n                    ", "@legal-doc": "usc"}}, {"#tail": ", and in lieu of filing a patent term extension application under ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 351 of the Public Health Service Act", "@value": "Public Health Service Act/s:351"}, "@entity-type": "law-citation", "#text": "\n                  ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                  ", "@entity-type": "uscode", "#text": "42 U.S.C. 262", "@value": "usc/42/262"}, "@parsable-cite": "usc/42/262", "#text": "\n                    ", "@legal-doc": "usc"}}]}, "enum": {"#tail": "\n              ", "#text": "(A)"}, "header": {"#tail": "\n              ", "#text": "In general"}, "#text": "\n              ", "@id": "H091372E9BC9A4153986672E4D37BE32E"}, {"#tail": "\n            ", "clause": [{"#tail": "\n              ", "subclause": [{"#tail": "\n                ", "text": {"#tail": "\n                ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " under ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ";", "@entity-type": "act", "#text": "subsection (b)(1)", "@value": "MODDERN Cures Act of 2013/s:201/ss:b/p:1", "@proposed": "true"}], "#text": "the listing of patents and applications for patents provided to the "}, "enum": {"#tail": "\n                  ", "#text": "(I)"}, "@id": "HC7B099B43C3F46D2B3CBAA0B09C24323", "#text": "\n                  "}, {"#tail": "\n                ", "text": {"#tail": "\n                ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "; and", "@entity-type": "act", "#text": "subsection (b)(1)", "@value": "MODDERN Cures Act of 2013/s:201/ss:b/p:1", "@proposed": "true"}, "#text": "any revisions to such listing as may be required for compliance with "}, "enum": {"#tail": "\n                  ", "#text": "(II)"}, "@id": "H62497D6B7880487E8BE0C951C0AB6F7E", "#text": "\n                  "}, {"#tail": "\n              ", "text": {"#tail": "\n                ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " may require from the patentee or patent applicant (as the case may be) of the waiver of patent rights required under ", "@entity-type": "federal-body", "#text": "Director", "@entity-id": "1344"}, {"#tail": ".", "@entity-type": "act", "#text": "subsection (b)(2)", "@value": "MODDERN Cures Act of 2013/s:201/ss:b/p:2", "@proposed": "true"}], "#text": "any documentation the "}, "enum": {"#tail": "\n                  ", "#text": "(III)"}, "@id": "H0D3BAE9618B44543AB7A35C3E11BE82A", "#text": "\n                  "}], "enum": {"#tail": "\n                ", "#text": "(i)"}, "header": {"#tail": "\n                ", "#text": "Submission"}, "text": {"#tail": "\n                ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " of not less than 2 months beginning on the date the ", "@entity-type": "federal-body", "#text": "Director", "@entity-id": "1344"}, {"#tail": " approves or licenses the dormant therapy, shall submit to the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": "\u2014", "@entity-type": "federal-body", "#text": "Director", "@entity-id": "1344"}], "#text": "The sponsor of the dormant therapy, within a period to be set by the "}, "#text": "\n                ", "@id": "H8EEC955D015049F180F87DD285641E3D"}, {"#tail": "\n            ", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " determines that the sponsor has not complied with the waiver requirements under ", "@entity-type": "federal-body", "#text": "Director", "@entity-id": "1344"}, {"#tail": ", after providing the sponsor the opportunity to remedy any insufficiency, the ", "@entity-type": "act", "#text": "subsection (c)", "@value": "MODDERN Cures Act of 2013/s:201/ss:c", "@proposed": "true"}, {"#tail": " shall so notify the ", "@entity-type": "federal-body", "#text": "Director", "@entity-id": "1344"}, {"#tail": " that the patent waiver requirements for designation have not been satisfied.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "If the "}, "enum": {"#tail": "\n                ", "#text": "(ii)"}, "header": {"#tail": "\n                ", "#text": "Failure to provide sufficient documentation of waiver"}, "#text": "\n                ", "@id": "H5626BB65F28345CB9D94BDF45F98E0E0"}], "enum": {"#tail": "\n              ", "#text": "(B)"}, "header": {"#tail": "\n              ", "#text": "Submission of final listing of patents and applications for patents following approval"}, "#text": "\n              ", "@id": "HDB7322EB23344A19914BED38FF29D8C0"}, {"#tail": "\n            ", "clause": [{"#tail": "\n              ", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " has notified the ", "@entity-type": "federal-body", "#text": "Director", "@entity-id": "1344"}, {"#tail": " of a determination under ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ", for each patent identified in a submission pursuant to ", "@entity-type": "act", "#text": "subparagraph (B)(ii)", "@value": "MODDERN Cures Act of 2013/s:201/ss:e/p:2/sp:B/cl:ii", "@proposed": "true"}, {"#tail": ", and for each patent issuing based upon an application for patent so identified, the ", "@entity-type": "act", "#text": "subparagraph (B)(i)", "@value": "MODDERN Cures Act of 2013/s:201/ss:e/p:2/sp:B/cl:i", "@proposed": "true"}, {"#tail": " shall, within the 3-month period beginning on the date of the submission, extend the patent to expire at the end of the protection period for the dormant therapy, if the patent would otherwise expire before the end of the protection period. If the ", "@entity-type": "federal-body", "#text": "Director", "@entity-id": "1344"}, {"#tail": " has so notified the ", "@entity-type": "federal-body", "#text": "Director", "@entity-id": "1344"}, {"#tail": " under ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ", the ", "@entity-type": "act", "#text": "subparagraph (B)(ii)", "@value": "MODDERN Cures Act of 2013/s:201/ss:e/p:2/sp:B/cl:ii", "@proposed": "true"}, {"#tail": " shall extend one such patent, selected by the sponsor, for the period that would have been applicable had an application for extension been filed under ", "@entity-type": "federal-body", "#text": "Director", "@entity-id": "1344"}, {"#tail": ", with respect to such patent.", "@entity-type": "uscode", "#text": "\n                    ", "external-xref": {"#tail": " of title 35, United States Code", "@parsable-cite": "usc/35/156", "#text": "section 156", "@legal-doc": "usc"}, "@value": "usc/35/156"}], "#text": "Unless the "}, "enum": {"#tail": "\n                ", "#text": "(i)"}, "header": {"#tail": "\n                ", "#text": "In general"}, "#text": "\n                ", "@id": "H93F66F679F6E4FB8A1E685CFE30F0765"}, {"#tail": "\n            ", "subclause": [{"#tail": "\n                ", "text": {"#tail": "\n                ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "; and", "@entity-type": "uscode", "#text": "\n                      ", "external-xref": {"#tail": " of title 35, United States Code", "@parsable-cite": "usc/35/156", "#text": "section 156(b)", "@legal-doc": "usc"}, "@value": "usc/35/156/b"}, "#text": "the rights under the patent shall be limited in the manner provided under "}, "enum": {"#tail": "\n                  ", "#text": "(I)"}, "@id": "HEC57DCEBC4D14F91B4EE4BA0CA05530E", "#text": "\n                  "}, {"#tail": "\n              ", "text": {"{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall be deemed to include forms of the active moiety of the dormant therapy and highly similar active moieties that might be approved by the ", "@entity-type": "uscode", "#text": "section 156(b)", "@value": "usc/35/156/b"}, {"#tail": " based upon an application filed under \n                      ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " or ", "@entity-type": "act", "#text": "section 505(b)(2)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:b/p:2"}, {"#tail": " (", "@entity-type": "act", "#text": "505(j) of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:j"}, {"#tail": ") or under ", "@entity-type": "uscode", "#text": "(j)", "@value": "usc/21/355/j"}], "#tail": "\n                ", "quote": [{"short-title": {"#tail": "\n                    ", "#text": "product"}, "#tail": " and ", "#text": "\n                      "}, {"short-title": {"#tail": "\n                    ", "#text": "approved product"}, "#tail": " in such ", "#text": "\n                      "}], "external-xref": {"#tail": ", ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                      ", "@entity-type": "uscode", "#text": "21 U.S.C. 355(b)(2)", "@value": "usc/21/355/b/2"}, "@parsable-cite": "usc/21/355", "#text": "\n                        ", "@legal-doc": "usc"}, "{http://namespaces.cato.org/catoxml}entity": {"#tail": " that references or otherwise relies upon the dormant therapy.", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 351(k) of the Public Health Service Act", "@value": "Public Health Service Act/s:351/ss:k"}, "@entity-type": "law-citation", "#text": "\n                      ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                      ", "@entity-type": "uscode", "#text": "42 U.S.C. 262(k)", "@value": "usc/42/262/k"}, "@parsable-cite": "usc/42/262", "#text": "\n                        ", "@legal-doc": "usc"}}, "#text": "the terms "}, "enum": {"#tail": "\n                  ", "#text": "(II)"}, "@id": "HE3FB96A1A8A841569A3C417CF023CF04", "#text": "\n                  "}], "enum": {"#tail": "\n                ", "#text": "(ii)"}, "header": {"#tail": "\n                ", "#text": "Application of certain provisions"}, "text": {"#tail": "\n                ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\u2014", "@entity-type": "act", "#text": "clause (i)", "@value": "MODDERN Cures Act of 2013/s:201/ss:e/p:2/sp:C/cl:i", "@proposed": "true"}, "#text": "During the period of an extension under "}, "#text": "\n                ", "@id": "H45A35D036AA24CAEB75869F8BCDA7EA8"}], "enum": {"#tail": "\n              ", "#text": "(C)"}, "header": {"#tail": "\n              ", "#text": "Extension of patents"}, "#text": "\n              ", "@id": "HDD0094C45BA243F0927C347C75FA38E3"}, {"#tail": "\n            ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", with respect to any patent listed (or patent issuing on an application listed) under ", "@entity-type": "uscode", "#text": "title 35, United States Code", "@value": "usc/35"}, {"#tail": " that would otherwise expire before the sponsor could make a submission under ", "@entity-type": "act", "#text": "subsection (b)(1)", "@value": "MODDERN Cures Act of 2013/s:201/ss:b/p:1", "@proposed": "true"}, {"#tail": ", the ", "@entity-type": "act", "#text": "subparagraph (B)", "@value": "MODDERN Cures Act of 2013/s:201/ss:e/p:2/sp:B", "@proposed": "true"}, {"#tail": ", upon application of the patentee, shall grant to the patentee an interim extension of such patent, subject to the limitations in ", "@entity-type": "federal-body", "#text": "Director", "@entity-id": "1344"}, {"#tail": ", for such period as may be necessary to permit the sponsor to submit the listing under ", "@entity-type": "uscode", "#text": "section 156(d)(5)(F) of such title 35", "@value": "usc/35/156/d/5/F"}, {"#tail": " and, if the patent is therein listed, to extend the patent as provided under ", "@entity-type": "act", "#text": "subparagraph (B)", "@value": "MODDERN Cures Act of 2013/s:201/ss:e/p:2/sp:B", "@proposed": "true"}, {"#tail": ". The ", "@entity-type": "act", "#text": "subparagraph (C)", "@value": "MODDERN Cures Act of 2013/s:201/ss:e/p:2/sp:C", "@proposed": "true"}, {"#tail": " may require, for any patent extended under this subparagraph, that the sponsor of the dormant therapy to which the patent relates provide periodic certifications that development of the dormant therapy is continuing. The ", "@entity-type": "federal-body", "#text": "Director", "@entity-id": "1344"}, {"#tail": " may terminate any interim extension for which a required certification has not been made.", "@entity-type": "federal-body", "#text": "Director", "@entity-id": "1344"}], "#text": "Notwithstanding any provision of "}, "enum": {"#tail": "\n              ", "#text": "(D)"}, "header": {"#tail": "\n              ", "#text": "Interim patent extensions"}, "#text": "\n              ", "@id": "H1B71DDCE07C2459CA8D29916B4C81019"}, {"#tail": "\n            ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall publish a notice of such extension and issue a certificate of extension described in ", "@entity-type": "federal-body", "#text": "Director", "@entity-id": "1344"}, {"#tail": ".", "@entity-type": "uscode", "#text": "\n                  ", "external-xref": {"#tail": " of title 35, United States Code", "@parsable-cite": "usc/35/156", "#text": "section 156(e)(1)", "@legal-doc": "usc"}, "@value": "usc/35/156/e/1"}], "#text": "For each patent that is extended under this paragraph, the "}, "enum": {"#tail": "\n              ", "#text": "(E)"}, "header": {"#tail": "\n              ", "#text": "Notice of extension"}, "#text": "\n              ", "@id": "H257E7CE863064AE9A9605C29B77F451F"}, {"#tail": "\n          ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", and each patent issuing based upon an application for patent so identified, that expires after the end of the protection period for the dormant therapy, the ", "@entity-type": "act", "#text": "subparagraph (B)(i)", "@value": "MODDERN Cures Act of 2013/s:201/ss:e/p:2/sp:B/cl:i", "@proposed": "true"}, {"#tail": " shall publish a notice that the patent is subject to the limited waiver of the right to enforce described in ", "@entity-type": "federal-body", "#text": "Director", "@entity-id": "1344"}, {"#tail": ".", "@entity-type": "act", "#text": "subsection (c)(1)", "@value": "MODDERN Cures Act of 2013/s:201/ss:c/p:1", "@proposed": "true"}], "#text": "For each patent identified in a submission under "}, "enum": {"#tail": "\n              ", "#text": "(F)"}, "header": {"#tail": "\n              ", "#text": "Notice of waiver"}, "#text": "\n              ", "@id": "HFF7F2258DFE548469DE0E73FB8A6F20B"}], "enum": {"#tail": "\n            ", "#text": "(2)"}, "header": {"#tail": "\n            ", "#text": "Patent term alignment with data package protection period"}, "#text": "\n            ", "@id": "H6A4EB253AA434BFA9CED8032BFB58CC4"}], "#text": "\n          ", "@id": "HA76D12F645104284B084D9C90A8C8F92"}, {"#tail": "\n        ", "text": {"{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", the protections otherwise applicable with respect to such medicine under \n              ", "@entity-type": "act", "#text": "subsection (a)", "@value": "MODDERN Cures Act of 2013/s:201/ss:a", "@proposed": "true"}, {"#tail": ", ", "@entity-type": "act", "#text": "sections 505A", "@value": "Federal Food, Drug, and Cosmetic Act/s:505A"}, {"#tail": ", and ", "@entity-type": "act", "#text": "505E", "@value": "Federal Food, Drug, and Cosmetic Act/s:505E"}, {"#tail": " (", "@entity-type": "act", "#text": "527 of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:527"}, {"#tail": ", ", "@entity-type": "uscode", "#text": "355f", "@value": "usc/21/355f"}, {"#tail": ") shall not apply. The preceding sentence shall not be construed to affect any protections applicable with respect to a drug, including a drug designated under ", "@entity-type": "uscode", "#text": "360cc", "@value": "usc/21/360cc"}, {"#tail": ", ", "@entity-type": "act", "#text": "sections 505A", "@value": "Federal Food, Drug, and Cosmetic Act/s:505A"}, {"#tail": ", and ", "@entity-type": "act", "#text": "505E", "@value": "Federal Food, Drug, and Cosmetic Act/s:505E"}, {"#tail": ".", "@entity-type": "act", "#text": "527", "@value": "Federal Food, Drug, and Cosmetic Act/s:527"}], "#tail": "\n        ", "external-xref": {"#tail": ", ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n              ", "@entity-type": "uscode", "#text": "21 U.S.C. 355a", "@value": "usc/21/355a"}, "@parsable-cite": "usc/21/355a", "#text": "\n                ", "@legal-doc": "usc"}, "{http://namespaces.cato.org/catoxml}entity": {"#tail": " for a rare disease or condition, under provisions other than such ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 526 of such Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:526"}, "@entity-type": "law-citation", "#text": "\n              ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n              ", "@entity-type": "uscode", "#text": "21 U.S.C. 360bb", "@value": "usc/21/360bb"}, "@parsable-cite": "usc/21/360bb", "#text": "\n                ", "@legal-doc": "usc"}}, "@display-inline": "yes-display-inline", "#text": "If a medicine has been designated as a dormant therapy under "}, "enum": {"#tail": "\n          ", "#text": "(f)"}, "header": {"#tail": "\n          ", "#text": "Certain FDA protections inapplicable"}, "#text": "\n          ", "@id": "H00E191AF9F924474A16B127623C0CE4A"}, {"#tail": "\n        ", "enum": {"#tail": "\n          ", "#text": "(g)"}, "header": {"#tail": "\n          ", "#text": "Development certifications"}, "paragraph": [{"#tail": "\n          ", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall require that the sponsor of a dormant therapy provide periodic certifications that development of the dormant therapy to address one or more unmet medical needs is continuing.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "The "}, "enum": {"#tail": "\n            ", "#text": "(1)"}, "header": {"#tail": "\n            ", "#text": "In general"}, "#text": "\n            ", "@id": "H2A125E11AB7C4E80B9F5A4D32DD33F97", "@commented": "no"}, {"#tail": "\n        ", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " concludes that the sponsor has not complied with ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ", after providing the sponsor the opportunity to remedy any insufficiency, the ", "@entity-type": "act", "#text": "paragraph (1)", "@value": "MODDERN Cures Act of 2013/s:201/ss:g/p:1", "@proposed": "true"}, {"#tail": " shall, for purposes of ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ", determine that the sponsor is not in compliance with the certification requirement under ", "@entity-type": "act", "#text": "subsection (d)(1)", "@value": "MODDERN Cures Act of 2013/s:201/ss:d/p:1", "@proposed": "true"}, {"#tail": ".", "@entity-type": "act", "#text": "paragraph (1)", "@value": "MODDERN Cures Act of 2013/s:201/ss:g/p:1", "@proposed": "true"}], "#text": "If the "}, "enum": {"#tail": "\n            ", "#text": "(2)"}, "header": {"#tail": "\n            ", "#text": "Determination of noncompliance"}, "#text": "\n            ", "@id": "H6F80DFCCC06C4D4980BB8C865493CC17", "@commented": "no"}], "#text": "\n          ", "@id": "H929BACB7B7514462B8652887746EECFF", "@commented": "no"}, {"#tail": "\n        ", "text": {"#tail": "\n        ", "#text": "Nothing in this section shall be construed as preventing a sponsor from collaborating with other entities in developing a dormant therapy or applying for a dormant therapy designation."}, "enum": {"#tail": "\n          ", "#text": "(h)"}, "header": {"#tail": "\n          ", "#text": "Collaboration"}, "#text": "\n          ", "@id": "H00C8324C9C904641AACEE142D756BD2E", "@commented": "no"}, {"#tail": "\n      ", "text": {"#tail": "\n          ", "#text": "For purposes of this section:"}, "enum": {"#tail": "\n          ", "#text": "(i)"}, "header": {"#tail": "\n          ", "#text": "Definitions"}, "paragraph": [{"#tail": "\n          ", "text": {"#tail": "\n            ", "quote": {"short-title": {"#tail": "\n              ", "#text": "address one or more unmet medical needs"}, "#tail": " refers to\u2014", "#text": "\n                "}, "#text": "The term "}, "enum": {"#tail": "\n            ", "#text": "(1)"}, "#text": "\n            ", "@id": "HEC9A6DBD3C074EC796C4731FA8584DC3", "subparagraph": [{"#tail": "\n            ", "text": {"#tail": "\n            ", "#text": "addressing a need for medicines for the treatment of one or more life-threatening or other serious diseases or conditions for which no therapy exists; or"}, "enum": {"#tail": "\n              ", "#text": "(A)"}, "@id": "H67629A166D9B4EAD939033C7C5E4C558", "#text": "\n              "}, {"#tail": "\n          ", "text": {"#tail": "\n              ", "#text": "if one or more therapies are available for the treatment of such a disease or condition, demonstrating through clinical investigations\u2014"}, "enum": {"#tail": "\n              ", "#text": "(B)"}, "clause": [{"#tail": "\n              ", "text": {"#tail": "\n              ", "#text": "one or more improved effects on serious outcomes of the disease or condition that are affected by alternative therapies, such as superiority of the medicine used alone or in combination with other therapies in an active controlled trial assessing an endpoint reflecting serious morbidity;"}, "enum": {"#tail": "\n                ", "#text": "(i)"}, "@id": "HEDA8EC612F3C410390F94997448398F7", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n              ", "#text": "one or more effects on serious outcomes of the disease or condition not known to be affected by alternative therapies, such as progressive disability in multiple sclerosis when alternative therapies have shown an effect on exacerbations but have not shown an effect on progressive disability;"}, "enum": {"#tail": "\n                ", "#text": "(ii)"}, "@id": "H2409C5B1E6594F80BD92B61713696B21", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n                ", "#text": "an ability\u2014"}, "enum": {"#tail": "\n                ", "#text": "(iii)"}, "subclause": [{"#tail": "\n                ", "text": {"#tail": "\n                ", "#text": "to provide one or more benefits in patients who are unable to tolerate or are unresponsive to alternative therapies, such as an antipsychotic agent that is effective in people failing standard therapy; or"}, "enum": {"#tail": "\n                  ", "#text": "(I)"}, "@id": "H13BC2FAA30C64B988F1F72185C72DC54", "#text": "\n                  "}, {"#tail": "\n              ", "text": {"#tail": "\n                ", "#text": "to be used effectively in combination with other critical agents that cannot be combined with alternative therapies;"}, "enum": {"#tail": "\n                  ", "#text": "(II)"}, "@id": "H3C2F83F46DB94A68AB57C3B8FB9B44A9", "#text": "\n                  "}], "#text": "\n                ", "@id": "H15EB3D0D2DF94920BFA842B6B7EACDCC"}, {"#tail": "\n              ", "text": {"#tail": "\n                ", "#text": "an ability to provide one or more benefits similar to those of alternative therapies while\u2014"}, "enum": {"#tail": "\n                ", "#text": "(iv)"}, "subclause": [{"#tail": "\n                ", "text": {"#tail": "\n                ", "#text": "avoiding serious toxicity that is present in alternative therapies; or"}, "enum": {"#tail": "\n                  ", "#text": "(I)"}, "@id": "H6DBCFBB7EEA84AD79054DB213DB14EA1", "#text": "\n                  "}, {"#tail": "\n              ", "text": {"#tail": "\n                ", "#text": "avoiding less serious toxicity that is common in alternative therapies and causes discontinuation of treatment of a life-threatening or serious disease; or"}, "enum": {"#tail": "\n                  ", "#text": "(II)"}, "@id": "H76430DB2FAFE452FBB9E61D757DCCBC7", "#text": "\n                  "}], "#text": "\n                ", "@id": "H414E15AA4408463DBEE663DB801F58F4"}, {"#tail": "\n            ", "text": {"#tail": "\n              ", "#text": "an ability to provide one or more benefits similar to those of alternative therapies but with improvement in some factor, such as compliance or convenience, that is shown to lead to improved effects on serious outcomes."}, "enum": {"#tail": "\n                ", "#text": "(v)"}, "@id": "HC2FD42223CF946D39288205A3E6F8E2B", "#text": "\n                "}], "#text": "\n              ", "@id": "HF41632F59CFA42FAAE08BB0AA5EEA778"}]}, {"#tail": "\n          ", "text": {"#tail": "\n          ", "quote": {"short-title": {"#tail": "\n              ", "#text": "Director"}, "#tail": " means the ", "#text": "\n                "}, "#text": "The term ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "federal-body", "#text": "Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office", "@entity-id": "1344"}}, "enum": {"#tail": "\n            ", "#text": "(2)"}, "@id": "H6D4778E11B8C44639EB9B2A3C19EF4D3", "#text": "\n            "}, {"#tail": "\n          ", "text": {"#tail": "\n          ", "quote": {"short-title": {"#tail": "\n              ", "#text": "dormant therapy"}, "#tail": " means a medicine designated as a dormant therapy under ", "#text": "\n                "}, "#text": "The term ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "act", "#text": "subsection (a)", "@value": "MODDERN Cures Act of 2013/s:201/ss:a", "@proposed": "true"}}, "enum": {"#tail": "\n            ", "#text": "(3)"}, "@id": "H0D10FDEC48374EC3A57782E42184595C", "#text": "\n            "}, {"#tail": "\n          ", "text": {"#tail": "\n            ", "quote": {"short-title": {"#tail": "\n              ", "#text": "protection period"}, "#tail": " for a dormant therapy means the period that\u2014", "#text": "\n                "}, "#text": "The term "}, "enum": {"#tail": "\n            ", "#text": "(4)"}, "#text": "\n            ", "@id": "H641730945A1A41C88B6317B9CFF3F44B", "subparagraph": [{"#tail": "\n            ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " first approves an application under ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "begins on the date on which the ", "{http://namespaces.cato.org/catoxml}entity": [{"#tail": " or ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 505(b) of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:b"}, "@entity-type": "law-citation", "#text": "\n                  ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                  ", "@entity-type": "uscode", "#text": "21 U.S.C. 355(b)", "@value": "usc/21/355/b"}, "@parsable-cite": "usc/21/355", "#text": "\n                    ", "@legal-doc": "usc"}}, {"#tail": " for the dormant therapy for any indication; and", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 351(a) of the Public Health Service Act", "@value": "Public Health Service Act/s:351/ss:a"}, "@entity-type": "law-citation", "#text": "\n                  ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                  ", "@entity-type": "uscode", "#text": "42 U.S.C. 262(a)", "@value": "usc/42/262/a"}, "@parsable-cite": "usc/42/262", "#text": "\n                    ", "@legal-doc": "usc"}}]}, "enum": {"#tail": "\n              ", "#text": "(A)"}, "@id": "HFEE2627F90114759A7891AF5F9D995CA", "#text": "\n              "}, {"#tail": "\n          ", "text": {"#tail": "\n            ", "#text": "ends on the date that is 15 years after the date of such approval."}, "enum": {"#tail": "\n              ", "#text": "(B)"}, "@id": "H002DAA08C2BF4CDB90EE0A74BB8DC598", "#text": "\n              "}]}, {"#tail": "\n        ", "text": {"#tail": "\n          ", "quote": {"short-title": {"#tail": "\n              ", "#text": "sponsor"}, "#tail": " for a dormant therapy is the person who takes responsibility for the designation and development of the dormant therapy. The sponsor may be a single entity or an entity collaborating with one or more other entities.", "#text": "\n                "}, "#text": "The term "}, "enum": {"#tail": "\n            ", "#text": "(5)"}, "#text": "\n            ", "@id": "HE7213278ECE94CACAAFB994D03B43FFB", "@commented": "no"}], "#text": "\n          ", "@id": "HAF137E3663F944CCA4820C12A229A2EC"}], "#text": "\n        ", "@id": "H8DC65581214743BEB9E1911E758A697F"}, {"#tail": "\n    ", "text": {"#tail": "\n        ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall enter into an arrangement with the Institute of Medicine (or, if the Institute declines, another appropriate entity)\u2014", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "Not later than one year after the date of the enactment of this Act, the ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n        ", "#text": "202."}, "header": {"#tail": "\n        ", "#text": "Study regarding new indications for existing therapies"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n        ", "#text": "to conduct a study on intellectual property laws and their impact on therapy and diagnostic development in order to formulate recommendations on how to facilitate the clinical evaluation and development of therapies currently available on the market for new potential indications; and"}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "@id": "H0C192C795C9D42A7A381596BB78CD450", "#text": "\n          "}, {"#tail": "\n      ", "text": {"#tail": "\n        ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " and the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " containing the results of such study.", "@entity-type": "federal-body", "#text": "Congress", "@entity-id": "0001"}], "#text": "not later than 18 months after such date of the enactment, to submit a report to the "}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "@id": "H2DD0DB853F404138B9A3DF0056330D11", "#text": "\n          "}], "#text": "\n        ", "@id": "HB9CEBDF8447549D89E443A23281009D0"}], "enum": {"#tail": "\n      ", "#text": "II"}, "header": {"#tail": "\n      ", "#text": "Capturing lost opportunities for patients"}, "#text": "\n      ", "@id": "HC8CEC43720D34568AC44D452D81D8341"}], "#tail": "\n", "section": [{"@section-type": "section-one", "#tail": "\n    ", "text": {"#tail": "\n    ", "quote": [{"short-title": {"#tail": "\n        ", "#text": "Modernizing Our Drug & Diagnostics Evaluation and Regulatory Network Cures Act of 2013"}, "#tail": " or the ", "#text": "\n          "}, {"short-title": {"#tail": "\n        ", "#text": "MODDERN Cures Act of 2013"}, "#tail": ".", "#text": "\n          "}], "#text": "This Act may be cited as the ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "1."}, "header": {"#tail": "\n      ", "#text": "Short title"}, "#text": "\n      ", "@id": "HC44C6D0E9D004A4DB4A7BB3723965271"}, {"#tail": "\n    ", "text": {"#tail": "\n      ", "#text": "The table of contents for this Act is as follows:", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "2."}, "header": {"#tail": "\n      ", "#text": "Table of contents"}, "toc": {"@container-level": "legis-body-container", "#tail": "\n    ", "@lowest-level": "section", "@regeneration": "yes-regeneration", "toc-entry": [{"@idref": "HC44C6D0E9D004A4DB4A7BB3723965271", "#tail": "\n        ", "#text": "Sec.\u20021.\u2002Short title.", "@level": "section"}, {"@idref": "H363FDF19068D401992C6D6CCA47B4DF0", "#tail": "\n        ", "#text": "Sec.\u20022.\u2002Table of contents.", "@level": "section"}, {"@idref": "H4CCB4A0AA1694B0D82B518C972DCE630", "#tail": "\n        ", "#text": "Sec.\u20023.\u2002Findings.", "@level": "section"}, {"@idref": "H4E0FBFFB8BCA425FACE4D6155A2C40CE", "#tail": "\n        ", "#text": "Sec.\u20024.\u2002Definitions.", "@level": "section"}, {"@idref": "H24A65B9C2A16445082C0EE3B3B8A9A35", "#tail": "\n        ", "#text": "Title I\u2014Advancing diagnostics for patients", "@level": "title"}, {"@idref": "HC72E66CD7B7D4F23A4532F9925B22DD0", "#tail": "\n        ", "#text": "Sec.\u2002101.\u2002Developing a common lexicon to facilitate progress on diagnostics.", "@level": "section"}, {"@idref": "H58BA5B094D8A46EBBEF2E7B3AC3344C2", "#tail": "\n        ", "#text": "Sec.\u2002102.\u2002Creating incentives for innovative diagnostics.", "@level": "section"}, {"@idref": "HDA8CEFDCAAC449B88CAFEE4F3EFE0AB3", "#tail": "\n        ", "#text": "Sec.\u2002103.\u2002Promoting the development of innovative diagnostics.", "@level": "section"}, {"@idref": "HC8CEC43720D34568AC44D452D81D8341", "#tail": "\n        ", "#text": "Title II\u2014Capturing lost opportunities for patients", "@level": "title"}, {"@idref": "H8DC65581214743BEB9E1911E758A697F", "#tail": "\n        ", "#text": "Sec.\u2002201.\u2002Dormant therapies.", "@level": "section"}, {"@idref": "HB9CEBDF8447549D89E443A23281009D0", "#tail": "\n      ", "#text": "Sec.\u2002202.\u2002Study regarding new indications for existing therapies.", "@level": "section"}], "@quoted-block": "no-quoted-block", "@lowest-bolded-level": "division-lowest-bolded", "#text": "\n        "}, "#text": "\n      ", "@id": "H363FDF19068D401992C6D6CCA47B4DF0"}, {"@section-type": "subsequent-section", "#tail": "\n    ", "text": {"#tail": "\n      ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " makes the following findings:", "@entity-type": "federal-body", "#text": "Congress", "@entity-id": "0001"}, "#text": "The ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "3."}, "header": {"#tail": "\n      ", "#text": "Findings"}, "paragraph": [{"#tail": "\n      ", "text": {"#tail": "\n      ", "#text": "More than 133 million Americans, or 45 percent of the population, have at least one chronic condition. A quarter of Americans have multiple chronic conditions.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(1)"}, "@id": "HBDC93468A9084DD9943A9CB54FC3513C", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n      ", "#text": "Chronic diseases have become the leading cause of death and disability in the United States. Seven out of every 10 deaths are attributable to chronic disease. Chronic diseases also compromise the quality of life of millions of Americans."}, "enum": {"#tail": "\n        ", "#text": "(2)"}, "@id": "H388A8877A7C743F595CFDEA9D3579B7D", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n      ", "#text": "Despite $80 billion spent annually on research and development, many diseases and conditions lack effective treatments."}, "enum": {"#tail": "\n        ", "#text": "(3)"}, "@id": "HA795167424CF4E929465FD9B556B0A49", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n      ", "#text": "Many commonly used drugs are effective in only 50 to 75 percent of the patient population, which can lead to devastating long-term side effects, resulting in the potential risks outweighing the benefits for some patients."}, "enum": {"#tail": "\n        ", "#text": "(4)"}, "@id": "HF9D34CD9159D403895D0D5E8269E4A9A", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n      ", "#text": "Advanced and innovative diagnostic tests have the potential to dramatically increase the efficacy and safety of drugs by better predicting how patients will respond to a given therapy."}, "enum": {"#tail": "\n        ", "#text": "(5)"}, "@id": "HF2EE7471E77F418693F91488604A8A06", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n      ", "#text": "Despite their promise, many drugs and diagnostics may go undeveloped due to uncertain regulatory and reimbursement processes, among other reasons."}, "enum": {"#tail": "\n        ", "#text": "(6)"}, "@id": "H1625250F7E504354A34D8ACB601CD2F8", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n      ", "#text": "In addition, there is reason to believe that potential treatments with tremendous value to patients are never developed or are discontinued during research and development due to insufficiencies in the intellectual property system."}, "enum": {"#tail": "\n        ", "#text": "(7)"}, "@id": "H12A42A1AD7B5434FADE977DFE2F1426F", "#text": "\n        "}, {"#tail": "\n    ", "text": {"#tail": "\n      ", "#text": "It is in the public interest to address the hurdles that may be precluding new treatments from reaching patients and to remove the disincentives for the development of therapies for these unmet needs."}, "enum": {"#tail": "\n        ", "#text": "(8)"}, "@id": "H695AF205BC9D443FB3799E230F5375AC", "#text": "\n        "}], "#text": "\n      ", "@id": "H4CCB4A0AA1694B0D82B518C972DCE630"}, {"#tail": "\n    ", "text": {"#tail": "\n      ", "#text": "In this Act:", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "4."}, "header": {"#tail": "\n      ", "#text": "Definitions"}, "paragraph": [{"#tail": "\n      ", "text": {"#tail": "\n      ", "term": {"#tail": " has the meaning given to that term in ", "#text": "biological product"}, "#text": "The term ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": ".", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 351 of the Public Health Service Act", "@value": "Public Health Service Act/s:351"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "uscode", "#text": "42 U.S.C. 262", "@value": "usc/42/262"}, "@parsable-cite": "usc/42/262", "#text": "\n              ", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n        ", "#text": "(1)"}, "@id": "HC5AAD814FC7D4DE1B19295146510C64A", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n      ", "term": {"#tail": " has the meaning given to that term in ", "#text": "drug"}, "#text": "The term ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": ".", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 201 of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:201"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "uscode", "#text": "21 U.S.C. 321", "@value": "usc/21/321"}, "@parsable-cite": "usc/21/321", "#text": "\n              ", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n        ", "#text": "(2)"}, "@id": "H1DCE301FA3934C72B15D1E525BBBBAE5", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n      ", "quote": {"short-title": {"#tail": "\n          ", "#text": "medicine"}, "#tail": " means a biological product or a drug.", "#text": "\n            "}, "#text": "The term ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(3)"}, "@id": "HC71FAA5D7CBB4F79BF6FAD0FE27D7F2D", "#text": "\n        "}, {"#tail": "\n    ", "text": {"#tail": "\n      ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "federal-body", "#text": "Secretary of Health and Human Services", "@entity-id": "7500"}, "term": {"#tail": " means the ", "#text": "Secretary"}, "#text": "The term "}, "enum": {"#tail": "\n        ", "#text": "(4)"}, "@id": "H6C342EA5DF114931B22F7A61F3B41499", "#text": "\n        "}], "#text": "\n      ", "@id": "H4E0FBFFB8BCA425FACE4D6155A2C40CE"}], "#text": "\n    ", "@id": "HC36741CED0E84E1ABEC6FA02F990610B"}, "metadata": {"#tail": "\n", "dublinCore": {"{http://purl.org/dc/elements/1.1/}date": {"#tail": "\n", "#text": "2013-09-17"}, "{http://purl.org/dc/elements/1.1/}format": {"#tail": "\n", "#text": "text/xml"}, "{http://purl.org/dc/elements/1.1/}language": {"#tail": "\n", "#text": "EN"}, "#tail": "\n", "{http://purl.org/dc/elements/1.1/}title": {"#tail": "\n", "#text": "113 HR 3116 IH: To promote the development of meaningful treatments for patients."}, "{http://purl.org/dc/elements/1.1/}rights": {"#tail": "\n", "#text": "Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain."}, "{http://purl.org/dc/elements/1.1/}publisher": {"#tail": "\n", "#text": "U.S. House of Representatives"}, "#text": "\n"}, "#text": "\n"}}}